1. Arriaga MB, Karim F, Queiroz ATL, Araújo-Pereira M, Barreto-Duarte B, Sales C, Moosa MS, Mazibuko M, Milne GL, Maruri F, Serezani CH, Koethe JR, Figueiredo MC, Kritski AL, Cordeiro-Santos M, Rolla VC, Sterling TR, Leslie A, Andrade BB. Effect of Dysglycemia on Urinary Lipid Mediator Profiles in Persons With Pulmonary Tuberculosis. Front Immunol. 2022 Jul 8;13:919802. doi: 10.3389/fimmu.2022.919802. PMID: 35874781; PMCID: PMC9304990.
  2. Wada PY, Costa AG, Araújo-Pereira M, Barreto-Duarte B, Souza AB, Rocha MS, Figueiredo MC, Turner MM, Rolla VC, Kritski AL, Cordeiro-Santos M, Andrade BB, Sterling TR, Rebeiro PF; Regional Prospective Observational Research in Tuberculosis (RePORT) Brazil Consortium. Possible Sex Difference in Latent Tuberculosis Infection Risk among Close Tuberculosis Contacts. Int J Infect Dis. 2022 Jul 14:S1201-9712(22)00426-X. doi: 10.1016/j.ijid.2022.07.031. Epub ahead of print. PMID: 35843494.
  3. Ridolfi F, Peetluk L, Amorim G, Turner M, Figueiredo M, Cordeiro-Santos M, Cavalcante S, Kritski A, Durovni B, Andrade B, Sterling TR, Rolla V; Regional Prospective Observational Research in Tuberculosis (RePORT)–Brazil Consortium. TB TREATMENT OUTCOMES IN BRAZIL: DIFFERENT PREDICTORS FOR EACH TYPE OF UNSUCCESSFUL OUTCOME. Clin Infect Dis. 2022 Jul 5:ciac541. doi: 10.1093/cid/ciac541. Epub ahead of print. PMID: 35788646.
  4. Nguenha D, Acacio S, Murias-Closas A, Ramanlal N, Saavedra B, Karajeanes E, Mudumane B, Mambuque E, Gomes N, Losada I, Oliveras L, Naueia E, Sterling TR, Amorim G, Moon TD, Menéndez C, Vaz P, López-Varela E, Garcia-Basteiro AL. Prevalence and clinical characteristics of pulmonary TB among pregnant and post-partum women. Int J Tuberc Lung Dis. 2022 Jul 1;26(7):641-649. doi: 10.5588/ijtld.21.0567. PMID: 35768920.
  5. Queiroz ATL, Araújo-Pereira M, Barreto-Duarte B, Gomes-Silva A, Costa AG, Andrade AMS, Miguez-Pinto JP, Spener-Gomes R, Souza AB, Benjamin A, Sant'Anna F, Figueiredo MC, Mave V, Salgame P, Ellner JJ, Sterling TR, Cordeiro-Dos-Santos M, Andrade BB, Rolla VC. Immunologic Biomarkers in Peripheral Blood of Persons With Tuberculosis and Advanced HIV. Front Immunol. 2022 Jun 10;13:890003. doi: 10.3389/fimmu.2022.890003. PMID: 35757685; PMCID: PMC9226490.
  6. Porter M, Choshi P, Pedretti S, Chimbetete T, Smith R, Meintjes G, Phillips E, Lehloenya R, Peter J. IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-line Anti-tuberculosis Drugs in an HIV Endemic Setting. J Invest Dermatol. 2022 Jun 1:S0022-202X(22)01500-7. doi: 10.1016/j.jid.2022.05.1059. Epub ahead of print. PMID: 35659939.
  7. Anderson K, Pietersen E, Shepherd BE, Bian A, Dheda K, Warren R, Sterling TR, van der Heijden YF. High mortality among patients hospitalized for drug-resistant tuberculosis with acquired second-line drug resistance and high HIV prevalence. HIV Med. 2022 May 24. doi: 10.1111/hiv.13318. Epub ahead of print. PMID: 35608016.
  8. Walker NF, Karim F, Moosa M, Moodley S, Mazibuko M, Khan K, Sterling TR, van der Heijden YF, Grant AD, Elkington PT, Pym A, Leslie A. Elevated Plasma Matrix Metalloproteinase-8 associates with Sputum Culture Positivity in Pulmonary Tuberculosis. J Infect Dis. 2022 May 1:jiac160. doi: 10.1093/infdis/jiac160. Epub ahead of print. PMID: 35510939.
  9. Antimycobacterial Susceptibility Testing Group. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment. Eur Respir J. 2022 Apr 14;59(4):2200166. doi: 10.1183/13993003.00166-2022. PMID: 35422426; PMCID: PMC9059840.
  10. Holzman SB, Perry A, Saleeb P, Pyan A, Keh C, Salcedo K, Narita M, Ahmed A, Miller TL, Pettit AC, Khurana R, Whipple M, Katz D, Largen A, Krueger A, Shah M. Evaluation of the latent tuberculosis care cascade among public health clinics in the United States. Clin Infect Dis. 2022 Apr 1:ciac248. doi: 10.1093/cid/ciac248. Epub ahead of print. PMID: 35363249.
  11. Crabtree-Ramirez B, Jenkins CA, Shepherd BE, Jayathilake K, Veloso VG, Carriquiry G, Gotuzzo E, Cortes CP, Padgett D, McGowan C, Sierra-Madero J, Koenig S, Pape JW, Sterling TR; CCASAnet Region of IeDEA. Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy. BMC Infect Dis. 2022 Apr 5;22(1):341. doi: 10.1186/s12879-022-07330-5. PMID: 35382770; PMCID: PMC8985331.
  12. Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Sales C, Miguez-Pinto JP, Nogueira EB, Nogueira BMF, Rocha MS, Souza AB, Benjamin A, de Oliveira JG, Moreira ASR, Queiroz ATL, Rodrigues MMS, Spener-Gomes R, Figueiredo MC, Durovni B, Cavalcante S, Lapa-E-Silva JR, Kristki AL, Cordeiro-Santos M, Sterling TR, Rolla VC, Andrade BB; RePORT-Brazil consortium. Prevalence and Clinical Profiling of Dysglycemia and HIV Infection in Persons With Pulmonary Tuberculosis in Brazil. Front Med (Lausanne). 2022 Jan 21;8:804173. doi: 10.3389/fmed.2021.804173. PMID: 35127760; PMCID: PMC8814308.
  13. Pietersen E, Anderson K, van der Heijden YF. Public health and hospital-based nursing intersection: Case study of drug-resistant tuberculosis patients. Public Health Nurs. 2022 Jan;39(1):170-179. doi: 10.1111/phn.13042. Epub 2022 Jan 6. PMID: 34990027; PMCID: PMC8766955.
  14. Haas DW, Abdelwahab MT, van Beek SW, Baker P, Maartens G, Bradford Y, Ritchie MD, Wasserman S, Meintjes G, Beeri K, Gandhi NR, Svensson EM, Denti P, Brust JCM. Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. J Infect Dis. 2022 Jan 29:jiac024. doi: 10.1093/infdis/jiac024. Epub ahead of print. PMID: 35091749.
  15. Calderon RI, Arriaga MB, Aliaga JG, Barreda NN, Sanabria OM, Barreto-Duarte B, Franco JPD, Lecca L, Andrade BB, Carvalho ACC, Kritski AL. Persistent dysglycemia is associated with unfavorable treatment outcomes in patients with pulmonary tuberculosis from Peru. Int J Infect Dis. 2022 Jan 13:S1201-9712(22)00013-3. doi: 10.1016/j.ijid.2022.01.012. Epub ahead of print. PMID: 35033658


  1. Mulenga H, Musvosvi M, Mendelsohn SC, Penn-Nicholson A, Kimbung Mbandi S, Fiore-Gartland A, Tameris M, Mabwe S, Africa H, Bilek N, Kafaar F, Khader SA, Carstens B, Hadley K, Hikuam C, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Nicol MP, Mbhele S, Van Heerden J, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Walzl G, Naidoo K, Churchyard G, Hatherill M, Scriba TJ; CORTIS Study Team. Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis. Am J Respir Crit Care Med. 2021 Dec 15;204(12):1463-1472. doi: 10.1164/rccm.202103-0548OC. PMID: 34520313
  2. Singhania A, Dubelko P, Kuan R, Chronister WD, Muskat K, Das J, Phillips EJ, Mallal SA, Seumois G, Vijayanand P, Sette A, Lerm M, Peters B, Lindestam Arlehamn C. CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature. EBioMedicine. 2021 Dec;74:103746. doi: 10.1016/j.ebiom.2021.103746. Epub 2021 Dec 11. PMID: 34902786; PMCID: PMC8671872
  3. Costa AG, Carvalho BKS, Araújo-Pereira M, Ibiapina HNS, Spener-Gomes R, Souza AB, Gomes-Silva A, Andrade AMS, Silva EC, Arriaga MB, Benjamin A, Rocha MS, Moreira ASR, Oliveira JG, Figueiredo MC, Turner MM, Durovni B, Cavalcante S, Kritski AL, Rolla VC, Sterling TR, Andrade BB, Cordeiro-Santos M; RePORT-Brazil Consortium. Lessons Learned from Implementation of an Interferon Gamma Release Assay to Screen for Latent Tuberculosis Infection in a Large Multicenter Observational Cohort Study in Brazil. Microbiol Spectr. 2021 Dec 22;9(3):e0116321. doi: 10.1128/Spectrum.01163-21. Epub 2021 Dec 1. PMID: 34851140; PMCID: PMC8635161
  4. Menzies NA, Quaife M, Allwood BW, Byrne AL, Coussens AK, Harries AD, Marx FM, Meghji J, Pedrazzoli D, Salomon JA, Sweeney S, van Kampen SC, Wallis RS, Houben RMGJ, Cohen T. Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. Lancet Glob Health. 2021 Dec;9(12):e1679-e1687. doi: 10.1016/S2214-109X(21)00367-3. PMID: 34798027; PMCID: PMC8609280
  5. Pearlman SI, Tang EM, Tao YK, Haselton FR. Controlling Droplet Marangoni Flows to Improve Microscopy-Based TB Diagnosis. Diagnostics (Basel). 2021 Nov 21;11(11):2155. doi: 10.3390/diagnostics11112155. PMID: 34829502; PMCID: PMC8618690
  6. Schwalb A, Cachay R, Meza E, Cáceres T, Blackman A, Maruri F, Sterling TR, Gotuzzo E. Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru. BMC Res Notes. 2021 Nov 14;14(1):413. doi: 10.1186/s13104-021-05832-0. PMID: 34776013; PMCID: PMC8591909
  7. Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A; IMPAACT P1078 study team. Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. Clin Infect Dis. 2021 Nov 2;73(9):e3555-e3562. doi: 10.1093/cid/ciaa1083. PMID: 32720695; PMCID: PMC8563205
  8. van der Heijden YF, Zhang B, Chougnet CA, Huaman MA. Cytomegalovirus Infection Is Associated With Increased Prevalence of Latent Tuberculosis Infection. Open Forum Infect Dis. 2021 Oct 23;8(11):ofab539. doi: 10.1093/ofid/ofab539. PMID: 35198641; PMCID: PMC8855520.
  9. Radtke KK, Ernest JP, Zhang N, Ammerman NC, Nuermberger E, Belknap R, Boyd R, Sterling TR, Savic RM. Comparative Efficacy of Rifapentine Alone and in Combination with Isoniazid for Latent Tuberculosis Infection: a Translational Pharmacokinetic-Pharmacodynamic Modeling Study. Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0170521. doi: 10.1128/AAC.01705-21. Epub 2021 Oct 4. PMID: 34606336; PMCID: PMC8597776
  10. Gupte AN, Kumar P, Araújo-Pereira M, Kulkarni V, Paradkar M, Pradhan N, Menon P, Chandrasekaran PD, Hanna LE, Yogendra Shivakumar SVB, Rockwood N, Du Bruyn E, Karyakarte R, Gaikwad S, Bollinger R, Golub J, Gupte N, Viswanathan V, Wilkinson RJ, Mave V, Babu S, Kornfeld H, Andrade BB, Gupta A. Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study. Eur Respir J. 2021 Oct 28:2100905. doi: 10.1183/13993003.00905-2021. Epub ahead of print. PMID: 34711538
  11. Arriaga MB, Araújo-Pereira M, Barreto-Duarte B, Nogueira B, Freire MVCNS, Queiroz ATL, Rodrigues MMS, Rocha MS, Souza AB, Spener-Gomes R, Carvalho ACC, Figueiredo MC, Turner MM, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB; RePORT Brazil consortium. The Effect of Diabetes and Prediabetes on Anti-tuberculosis Treatment Outcomes: A Multi-center Prospective Cohort Study. J Infect Dis. 2021 Oct 15:jiab427. doi: 10.1093/infdis/jiab427. Epub ahead of print. PMID: 34651642
  12. Tibúrcio R, Barreto-Duarte B, Naredren G, Queiroz ATL, Anbalagan S, Nayak K, Ravichandran N, Subramani R, Antonelli LRV, Satagopan K, Anbalagan K, Porter BO, Sher A, Swaminathan S, Sereti I, Andrade BB. Dynamics of T-Lymphocyte Activation Related to Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in Persons With Advanced HIV. Front Immunol. 2021 Oct 7;12:757843. doi: 10.3389/fimmu.2021.757843. PMID: 34691079; PMCID: PMC8529328
  13. Souza AB, Arriaga MB, Amorim G, Araújo-Pereira M, Nogueira BMF, Queiroz ATL, Figueiredo MC, Rocha MS, Benjamin A, Moreira ASR, Oliveira JG, Rolla V, Durovni B, Lapa E Silva JR, Kritski AL, Cavalcante S, Sterling T, Andrade BB, Cordeiro-Santos M; RePORT Brazil consortium. Determinants of losses in the latent tuberculosis infection cascade of care in Brazil. BMJ Glob Health. 2021 Sep;6(9):e005969. doi: 10.1136/bmjgh-2021-005969. PMID: 34518204
  14. Churchyard G, Cárdenas V, Chihota V, Mngadi K, Sebe M, Brumskine W, Martinson N, Yimer G, Wang SH, Garcia-Basteiro AL, Nguenha D, Masilela L, Waggie Z, van den Hof S, Charalambous S, Cobelens F, Chaisson RE, Grant AD, Fielding KL; WHIP3TB Study Team*. Annual Tuberculosis Preventive Therapy for Persons With HIV Infection : A Randomized Trial. Ann Intern Med. 2021 Aug 24. doi: 10.7326/M20-7577. Epub ahead of print. PMID: 34424730
  15. Bohrer AC, Castro E, Hu Z, Queiroz ATL, Tocheny CE, Assmann M, Sakai S, Nelson C, Baker PJ, Ma H, Wang L, Zilu W, du Bruyn E, Riou C, Kauffman KD; Tuberculosis Imaging Program, Moore IN, Del Nonno F, Petrone L, Goletti D, Martineau AR, Lowe DM, Cronan MR, Wilkinson RJ, Barry CE, Via LE, Barber DL, Klion AD, Andrade BB, Song Y, Wong KW, Mayer-Barber KD. Eosinophils are part of the granulocyte response in tuberculosis and promote host resistance in mice. J Exp Med. 2021 Oct 4;218(10):e20210469. doi: 10.1084/jem.20210469. Epub 2021 Aug 4. PMID: 34347010; PMCID: PMC8348215
  16. Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Edward VA, Rassool M, Ahmed K, Fielding K, Ahidjo BA, Vangu MDT, Churchyard G. Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021 Aug;9(8):897-908. doi: 10.1016/S2213-2600(20)30448-3. Epub 2021 Mar 16. Erratum in: Lancet Respir Med. 2021 Jun;9(6):e55. PMID: 33740465; PMCID: PMC8332197
  17. Haas DW, Mngqibisa R, Francis J, McIlleron H, Robinson JA, Kendall MA, Baker P, Mawlana S, Badal-Faesen S, Angira F, Omoz-Oarhe A, Samaneka WP, Denti P, Cohn SE; AIDS Clinical Trials Group A5338 Study Team. Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenet Genomics. 2021 Aug 6. doi: 10.1097/FPC.0000000000000448. Epub ahead of print. PMID: 34369424
  18. Bruyn ED, Fukutani KF, Rockwood N, Schutz C, Meintjes G, Arriaga MB, Cubillos-Angulo JM, Tibúrcio R, Sher A, Riou C, Wilkinson KA, Andrade BB, Wilkinson RJ. Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis. Lancet Microbe. 2021 Aug;2(8):e375-e385. doi: 10.1016/s2666-5247(21)00037-9. Epub 2021 May 18. PMID: 34386782; PMCID: PMC8357308
  19. Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, Evans S, Gupta A. Using a Composite Maternal-Infant Outcome Measure in Tuberculosis-Prevention Studies Among Pregnant Women. Clin Infect Dis. 2021 Aug 2;73(3):e587-e593. doi: 10.1093/cid/ciaa1674. PMID: 33146706; PMCID: PMC8326545
  20. Moodley N, Velen K, Saimen A, Zakhura N, Churchyard G, Charalambous S. Digital chest radiography enhances screening efficiency for pulmonary tuberculosis in primary health clinics, South Africa. Clin Infect Dis. 2021 Jul 27:ciab644. doi: 10.1093/cid/ciab644. Epub ahead of print. PMID: 34313729
  21. Barreto-Duarte B, Araújo-Pereira M, Nogueira BMF, Sobral L, Rodrigues MMS, Queiroz ATL, Rocha MS, Nascimento V, Souza AB, Cordeiro-Santos M, Kritski AL, Sterling TR, Arriaga MB, Andrade BB. Tuberculosis Burden and Determinants of Treatment Outcomes According to Age in Brazil: A Nationwide Study of 896,314 Cases Reported Between 2010 and 2019. Front Med (Lausanne). 2021 Jul 27;8:706689. doi: 10.3389/fmed.2021.706689. PMID: 34386510; PMCID: PMC8354381
  22. Simmons JD, Van PT, Stein CM, Chihota V, Ntshiqa T, Maenetje P, Peterson GJ, Reynolds A, Benchek P, Velen K, Fielding KL, Grant AD, Graustein AD, Nguyen FK, Seshadri C, Gottardo R, Mayanja-Kizza H, Wallis RS, Churchyard G, Boom WH, Hawn TR. Monocyte metabolic transcriptional programs associate with resistance to tuberculin skin test/interferon-γ release assay conversion. J Clin Invest. 2021 Jul 15;131(14):e140073. doi: 10.1172/JCI140073. PMID: 34111032; PMCID: PMC8279582
  23. Carvalho ACC, Amorim G, Melo MGM, Silveira AKA, Vargas PHL, Moreira ASR, Rocha MS, Souza AB, Arriaga MB, Araújo-Pereira M, Figueiredo MC, Durovni B, Lapa-E-Silva JR, Cavalcante S, Rolla VC, Sterling TR, Cordeiro-Santos M, Andrade BB, Silva EC, Kritski AL; RePORT Brazil consortium. Pre-Treatment Neutrophil Count as a Predictor of Antituberculosis Therapy Outcomes: A Multicenter Prospective Cohort Study. Front Immunol. 2021 Jul 2;12:661934. doi: 10.3389/fimmu.2021.661934. PMID: 34276654; PMCID: PMC8284392.
  24. Peetluk LS, Rebeiro PF, Ridolfi FM, Andrade BB, Cordeiro-Santos M, Kritski A, Durovni B, Calvacante S, Figueiredo MC, Haas DW, Liu D, Rolla VC, Sterling TR; Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network. A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes. Clin Infect Dis. 2021 Jul 2:ciab598. doi: 10.1093/cid/ciab598. Epub ahead of print. PMID: 34214166
  25. Costa DL, Amaral EP, Namasivayam S, Mittereder LR, Andrade BB, Sher A. Enhancement of CD4+ T Cell Function as a Strategy for Improving Antibiotic Therapy Efficacy in Tuberculosis: Does It Work? Front Cell Infect Microbiol. 2021 Jun 21;11:672527. doi: 10.3389/fcimb.2021.672527. PMID: 34235093; PMCID: PMC8256258
  26. Cubillos-Angulo JM, Fernandes CD, Araújo DN, Carmo CA, Arriaga MB, Andrade BB. The influence of single nucleotide polymorphisms of NOD2 or CD14 on the risk of Mycobacterium tuberculosis diseases: a systematic review. Syst Rev. 2021 Jun 9;10(1):174. doi: 10.1186/s13643-021-01729-y. PMID: 34108050; PMCID: PMC8191055
  27. Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, Hadley K, Hikuam C, Musvosvi M, Bilek N, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Sumner T, White RG, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS-HR Study Team. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. Lancet Glob Health. 2021 Jun;9(6):e841-e853. doi: 10.1016/S2214-109X(21)00045-0. Epub 2021 Apr 13. PMID: 33862012; PMCID: PMC8131200.
  28. Krishnan S, Queiroz ATL, Gupta A, Gupte N, Bisson GP, Kumwenda J, Naidoo K, Mohapi L, Mave V, Mngqibisa R, Lama JR, Hosseinipour MC, Andrade BB, Karakousis PC. Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV. Front Immunol. 2021 Jun 8;12:676980. doi: 10.3389/fimmu.2021.676980. PMID: 34168648; PMCID: PMC8217878
  29. Shivakoti R, Newman JW, Hanna LE, Queiroz ATL, Borkowski K, Gupte AN, Paradkar M, Satyamurthi P, Kulkarni V, Selva M, Pradhan N, Shivakumar SVBY, Natarajan S, Karunaianantham R, Gupte N, Thiruvengadam K, Fiehn O, Bharadwaj R, Kagal A, Gaikwad S, Sangle S, Golub JE, Andrade BB, Mave V, Gupta A, Padmapriyadarsini C. Host Lipidome and Tuberculosis Treatment Failure. Eur Respir J. 2021 Jun 17:2004532. doi: 10.1183/13993003.04532-2020. Epub ahead of print. PMID: 34375300
  30. Ley SD, Pillay S, Streicher EM, van der Heijden YF, Sirgel F, Derendinger B, de Kock M, Gagneux S, Warren RM, Theron G, de Vos M. Melting the eis: Nondetection of Kanamycin Resistance Markers by Routine Diagnostic Tests and Identification of New eis Promoter Variants. Antimicrob Agents Chemother. 2021 Jun 17;65(7):e0250220. doi: 10.1128/AAC.02502-20. Epub 2021 Jun 17. PMID: 33903113; PMCID: PMC8218670
  31. Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Mbandi SK, Borate B, Hadley K, Hikuam C, Musvosvi M, Bilek N, Erasmus M, Jaxa L, Raphela R, Nombida O, Kaskar M, Sumner T, White RG, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Scriba TJ, Hatherill M; CORTIS-HR Study Team. Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study. Lancet Glob Health. 2021 Jun;9(6):e841-e853. doi: 10.1016/S2214-109X(21)00045-0. Epub 2021 Apr 13. PMID: 33862012; PMCID: PMC8131200
  32. Maruri F, Guo Y, Blackman A, van der Heijden YF, Rebeiro PF, Sterling TR. Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. Clin Infect Dis. 2021 Jun 1;72(11):1910-1918. doi: 10.1093/cid/ciaa496. PMID: 32348473; PMCID: PMC8315129
  33. Arriaga MB, Rocha MS, Nogueira B, Nascimento V, Araújo-Pereira M, Souza AB, Andrade AMS, Costa AG, Gomes-Silva A, Silva EC, Figueiredo MC, Turner MM, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB; RePORT Brazil consortium. The Effect of Diabetes and Prediabetes on Mycobacterium tuberculosis Transmission to Close Contacts. J Infect Dis. 2021 May 19:jiab264. doi: 10.1093/infdis/jiab264. Epub ahead of print. PMID: 34008010
  34. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. PMID: 33951360; PMCID: PMC8282329
  35. Gausi K, Wiesner L, Norman J, Wallis CL, Onyango-Makumbi C, Chipato T, Haas DW, Browning R, Chakhtoura N, Montepiedra G, Aaron L, McCarthy K, Bradford S, Vhembo T, Stranix-Chibanda L, Masheto GR, Violari A, Mmbaga BT, Aurpibul L, Bhosale R, Nevrekhar N, Rouzier V, Kabugho E, Mutambanengwe M, Chanaiwa V, Nyati M, Mhembere T, Tongprasert F, Hesseling A, Shin K, Zimmer B, Costello D, Jean-Philippe P, Sterling TR, Theron G, Weinberg A, Gupta A, Denti P; IMPAACT P1078 (TB APPRISE) Study Group Team. Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. Clin Pharmacol Ther. 2021 Apr;109(4):1034-1044. doi: 10.1002/cpt.2044. Epub 2020 Oct 16. PMID: 32909316
  36. Vinhaes CL, Sheikh V, Oliveira-de-Souza D, Wang J, Rupert A, Roby G, Arriaga MB, Fukutani KF, Sawe F, Shaffer D, Ananworanich J, Phanuphak N, Andrade BB, Sereti I. An Inflammatory Composite Score Predicts Mycobacterial Immune Reconstitution Inflammatory Syndrome in People with Advanced HIV: A Prospective International Cohort Study. J Infect Dis. 2021 Apr 8;223(7):1275-1283. doi: 10.1093/infdis/jiaa484. PMID: 32761193; PMCID: PMC8030712
  37. Oleaga-Quintas C, de Oliveira-Júnior EB, Rosain J, Rapaport F, Deswarte C, Guérin A, Sajjath SM, Zhou YJ, Marot S, Lozano C, Branco L, Fernández-Hidalgo N, Lew DB, Brunel AS, Thomas C, Launay E, Arias AA, Cuffel A, Monjo VC, Neehus AL, Marques L, Roynard M, Moncada-Vélez M, Gerçeker B, Colobran R, Vigué MG, Lopez-Herrera G, Berron-Ruiz L, Méndez NHS, O'Farrill Romanillos P, Le Voyer T, Puel A, Bellanné-Chantelot C, Ramirez KA, Lorenzo-Diaz L, Alejo NR, de Diego RP, Condino-Neto A, Mellouli F, Rodriguez-Gallego C, Witte T, Restrepo JF, Jobim M, Boisson-Dupuis S, Jeziorski E, Fieschi C, Vogt G, Donadieu J, Pasquet M, Vasconcelos J, Ardeniz FO, Martínez-Gallo M, Campos RA, Jobim LF, Martínez-Barricarte R, Liu K, Cobat A, Abel L, Casanova JL, Bustamante J. Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance. J Clin Immunol. 2021 Apr;41(3):639-657. doi: 10.1007/s10875-020-00930-3. Epub 2021 Jan 8. PMID: 33417088
  38. Baliashvili D, Gandhi NR, Kim S, Hughes M, Mave V, Mendoza-Ticona A, Gonzales P, Kim N, Selvamuthu P, Badal-Faesen S, Upton C, Naini L, Smith E, Gupta A, Churchyard G, Swindells S, Hesseling A, Shah NS. Resistance to Mycobacterium tuberculosis infection among household contacts: a multinational study. Clin Infect Dis. 2021 Mar 27:ciab269. doi: 10.1093/cid/ciab269. Epub ahead of print. PMID: 33772550
  39. Manesen R, Mekler KA, Molobi TR, Tyiki AA, Madlavu MJ, Velen K, Charalambous S, van der Heijden YF. Data quality assessment of a South African electronic registry for drug-resistant TB, 2015-2016. Public Health Action. 2021 Mar 21;11(1):33-39. doi: 10.5588/pha.20.0031. PMID: 33777719; PMCID: PMC7987250
  40. Spener-Gomes R, Costa AG, de Melo HF, de Souza AB, Beraldi-Magalhães F, Jesus JS, Arriaga MB, Kritski A, Safe I, Andrade BB, Trajman A, Cordeiro-Santos M. Examination of respiratory specimens improves microbiological diagnosis of patients with presumptive extrapulmonary tuberculosis. Int J Infect Dis. 2021 Mar 12:S1201-9712(21)00240-X. doi: 10.1016/j.ijid.2021.03.022. Epub ahead of print. PMID: 33722683
  41. Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, Mulenga H, Kimbung Mbandi S, Borate B, Mendelsohn SC, Hadley K, Hikuam C, Kaskar M, Musvosvi M, Bilek N, Self S, Sumner T, White RG, Erasmus M, Jaxa L, Raphela R, Innes C, Brumskine W, Hiemstra A, Malherbe ST, Hassan-Moosa R, Tameris M, Walzl G, Naidoo K, Churchyard G, Hatherill M; CORTIS-01 Study Team. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. Lancet Infect Dis. 2021 Mar;21(3):354-365. doi: 10.1016/S1473-3099(20)30914-2. Epub 2021 Jan 25. PMID: 33508224; PMCID: PMC7907670
  42. Peetluk LS, Ridolfi FM, Rebeiro PF, Liu D, Rolla VC, Sterling TR. Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults. BMJ Open. 2021 Mar 2;11(3):e044687. doi: 10.1136/bmjopen-2020-044687. PMID: 33653759; PMCID: PMC7929865
  43. Demers AM, Kim S, McCallum S, Eisenach K, Hughes M, Naini L, Mendoza-Ticona A, Pradhan N, Narunsky K, Poongulali S, Badal-Faesen S, Upton C, Smith E, Shah NS, Churchyard G, Gupta A, Hesseling A, Swindells S; ACTG A5300/IMPAACT I2003 PHOENIx Feasibility study team. Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial. BMC Infect Dis. 2021 Feb 24;21(1):205. doi: 10.1186/s12879-021-05884-4. PMID: 33627075; PMCID: PMC7903693
  44. Kulkarni V, Queiroz ATL, Sangle S, Kagal A, Salvi S, Gupta A, Ellner J, Kadam D, Rolla VC, Andrade BB, Salgame P, Mave V. A Two-Gene Signature for Tuberculosis Diagnosis in Persons With Advanced HIV. Front Immunol. 2021 Feb 22;12:631165. doi: 10.3389/fimmu.2021.631165. PMID: 33692804; PMCID: PMC7937880
  45. van der Horst M , Karamchand L , Bauer WS , Nel AJM , Blackburn JM , Wright DW . The cyanobacterial lectin, microvirin-N, enhances the specificity and sensitivity of lipoarabinomannan-based TB diagnostic tests. Analyst. 2021 Feb 21;146(4):1207-1215. doi: 10.1039/d0an01725f. Epub 2020 Dec 24. PMID: 33367346
  46. Amaral EP, Vinhaes CL, Oliveira-de-Souza D, Nogueira B, Akrami KM, Andrade BB. The Interplay Between Systemic Inflammation, Oxidative Stress, and Tissue Remodeling in Tuberculosis. Antioxid Redox Signal. 2021 Feb 20;34(6):471-485. doi: 10.1089/ars.2020.8124. Epub 2020 Jun 19. PMID: 32559410
  47. Blackman A, Morrison B, Maruri F, van der Heijden Y, Nochowicz CH, Guo Y, Scholz M, Rustad T, Sherman DR, Sterling TR. Re-evaluation of a novel resistance mutation in eccC5 of the ESX-5 secretion system in ofloxacin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 2021 Feb 11;76(3):820-822. doi: 10.1093/jac/dkaa507. PMID: 33367727; PMCID: PMC7879138
  48. Safe IP, Amaral EP, Araújo-Pereira M, Lacerda MVG, Printes VS, Souza AB, Beraldi-Magalhães F, Monteiro WM, Sampaio VS, Barreto-Duarte B, Andrade AMS, Spener-Gomes R, Costa AG, Cordeiro-Santos M, Andrade BB. Adjunct N-Acetylcysteine Treatment in Hospitalized Patients With HIV-Associated Tuberculosis Dampens the Oxidative Stress in Peripheral Blood: Results From the RIPENACTB Study Trial. Front Immunol. 2021 Feb 4;11:602589. doi: 10.3389/fimmu.2020.602589. PMID: 33613521; PMCID: PMC7889506
  49. Haas DW, Podany AT, Bao Y, Swindells S, Chaisson RE, Mwelase N, Supparatpinyo K, Mohapi L, Gupta A, Benson CA, Baker P, Fletcher CV. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. Pharmacogenet Genomics. 2021 Jan;31(1):17-27. doi: 10.1097/FPC.0000000000000417. PMID: 32815870; PMCID: PMC7655626
  50. Naik S, Alexander M, Kumar P, Kulkarni V, Deshpande P, Yadana S, Leu CS, Araújo-Pereira M, Andrade BB, Bhosale R, Babu S, Gupta A, Mathad JS, Shivakoti R. Systemic Inflammation in Pregnant Women With Latent Tuberculosis Infection. Front Immunol. 2021 Jan 27;11:587617. doi: 10.3389/fimmu.2020.587617. PMID: 33584652; PMCID: PMC7873478
  51. Gupte AN, Selvaraju S, Gaikwad S, Mave V, Kumar P, Babu S, Andrade BB, Checkley W, Bollinger R, Gupta A. Higher interleukin-6 levels and changes in transforming growth factor-β are associated with lung impairment in pulmonary tuberculosis. ERJ Open Res. 2021 Jan 18;7(1):00390-2020. doi: 10.1183/23120541.00390-2020. PMID: 33532468; PMCID: PMC7836581
  52. Costa DL, Amaral EP, Namasivayam S, Mittereder LR, Fisher L, Bonfim CC, Sardinha-Silva A, Thompson RW, Hieny SE, Andrade BB, Sher A. Heme oxygenase-1 inhibition promotes IFNγ- and NOS2-mediated control of Mycobacterium tuberculosis infection. Mucosal Immunol. 2021 Jan;14(1):253-266. doi: 10.1038/s41385-020-00342-x. Epub 2020 Aug 29. PMID: 32862202; PMCID: PMC7796944
  53. Auld SC, Kornfeld H, Maenetje P, Mlotshwa M, Chase W, Vangu MD, Torigian DA, Wallis RS, Churchyard G, Bisson GP. Pulmonary restriction predicts long-term pulmonary impairment in people with HIV and tuberculosis. BMC Pulm Med. 2021 Jan 7;21(1):19. doi: 10.1186/s12890-020-01368-4. PMID: 33413293; PMCID: PMC7791797
  54. Huaman MA, De Cecco CN, Bittencourt MS, Ticona E, Kityo C, Ballena I, Nalukwago S, Nazzinda R, Ticona C, Azañero R, Zhang B, Farquhar C, Hawn TR, Sterling TR, Fichtenbaum CJ, Longenecker CT. Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. Clin Infect Dis. 2021 Jan 3:ciaa1934. doi: 10.1093/cid/ciaa1934. Epub ahead of print. PMID: 33388766



  1. Barreto-Duarte B, Sterling TR, Fiske CT, Almeida A, Nochowicz CH, Smith RM, Barnett L, Warren C, Blackman A, Lapa E Silva JR, Andrade BB, Kalams SA. Increased Frequency of Memory CD4+ T-Cell Responses in Individuals With Previously Treated Extrapulmonary Tuberculosis. Front Immunol. 2020 Dec 17;11:605338. doi: 10.3389/fimmu.2020.605338. PMID: 33391271; PMCID: PMC7774017
  2. Manabe YC, Andrade BB, Gupte N, Leong S, Kintali M, Matoga M, Riviere C, Samaneka W, Lama JR, Naidoo K, Zhao Y, Johnson WE, Ellner JJ, Hosseinipour MC, Bisson GP, Salgame P, Gupta A. A Parsimonious Host Inflammatory Biomarker Signature Predicts Incident Tuberculosis and Mortality in Advanced Human Immunodeficiency Virus. Clin Infect Dis. 2020 Dec 17;71(10):2645-2654. doi: 10.1093/cid/ciz1147. PMID: 31761933; PMCID: PMC7744990
  3. Arriaga MB, Amorim G, Queiroz ATL, Rodrigues MMS, Araújo-Pereira M, Nogueira BMF, Souza AB, Rocha MS, Benjamin A, Moreira ASR, de Oliveira JG, Figueiredo MC, Turner MM, Alves K, Durovni B, Lapa-E-Silva JR, Kritski AL, Cavalcante S, Rolla VC, Cordeiro-Santos M, Sterling TR, Andrade BB; RePORT Brazil consortium. Novel Stepwise Approach to Assess Representativeness of a Large Multicenter Observational Cohort of Tuberculosis Patients: The Example of RePORT Brazil. Int J Infect Dis. 2020 Nov 13:S1201-9712(20)32452-8. doi: 10.1016/j.ijid.2020.11.140. Epub ahead of print. PMID: 33197582; PMCID: PMC7959330
  4. Dutta NK, Tornheim JA, Fukutani KF, Paradkar M, Tiburcio RT, Kinikar A, Valvi C, Kulkarni V, Pradhan N, Shivakumar SVBY, Kagal A, Gupte A, Gupte N, Mave V, Gupta A, Andrade BB, Karakousis PC. Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children. Sci Rep. 2020 Nov 11;10(1):19527. doi: 10.1038/s41598-020-75513-8. PMID: 33177551; PMCID: PMC7658223
  5. Silveira-Mattos PS, Barreto-Duarte B, Vasconcelos B, Fukutani KF, Vinhaes CL, Oliveira-De-Souza D, Ibegbu CC, Figueiredo MC, Sterling TR, Rengarajan J, Andrade BB. Differential Expression of Activation Markers by Mycobacterium tuberculosis-specific CD4+ T Cell Distinguishes Extrapulmonary From Pulmonary Tuberculosis and Latent Infection. Clin Infect Dis. 2020 Nov 5;71(8):1905-1911. doi: 10.1093/cid/ciz1070. PMID: 31665254
  6. Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, Evans S, Gupta A. Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women. Clin Infect Dis. 2020 Nov 4:ciaa1674. doi: 10.1093/cid/ciaa1674. Epub ahead of print. PMID: 33146706
  7. Reichler MR, Khan A, Yuan Y, Chen B, McAuley J, Mangura B, Sterling TR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Duration of Exposure Among Close Contacts of Patients With Infectious Tuberculosis and Risk of Latent Tuberculosis Infection. Clin Infect Dis. 2020 Oct 23;71(7):1627-1634. doi: 10.1093/cid/ciz1044. PMID: 32044987
  8. Sterling TR, Lin PL. Treatment of latent M. tuberculosis infection and use of antiretroviral therapy to prevent tuberculosis. J Clin Invest. 2020 Oct 1;130(10):5102-5104. doi: 10.1172/JCI137294. PMID: 32831291; PMCID: PMC7524504
  9. Merrikh H, Kohli RM. Targeting evolution to inhibit antibiotic resistance. FEBS J. 2020 Oct;287(20):4341-4353. doi: 10.1111/febs.15370. Epub 2020 Jun 8. PMID: 32434280; PMCID: PMC7578009
  10. Demitto FO, Araújo-Pereira M, Schmaltz CA, Sant'Anna FM, Arriaga MB, Andrade BB, Rolla VC. Impact of Persistent Anemia on Systemic Inflammation and Tuberculosis Outcomes in Persons Living With HIV. Front Immunol. 2020 Sep 24;11:588405. doi: 10.3389/fimmu.2020.588405. PMID: 33072136; PMCID: PMC7541849
  11. Narendran G, Jyotheeswaran K, Senguttuvan T, Vinhaes CL, Santhanakrishnan RK, Manoharan T, Selvaraj A, Chandrasekaran P, Menon PA, Bhavani KP, Reddy D, Narayanan R, Subramanyam B, Sathyavelu S, Krishnaraja R, Kalirajan P, Angamuthu D, Susaimuthu SM, Ganesan RRK, Tripathy SP, Swaminathan S, Andrade BB. Characteristics of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and its influence on tuberculosis treatment outcomes in persons living with HIV. Int J Infect Dis. 2020 Sep;98:261-267. doi: 10.1016/j.ijid.2020.06.097. Epub 2020 Jul 2. PMID: 32623087
  12. Ndlovu LN, Peetluk L, Moodley S, Nhamoyebonde S, Ngoepe AT, Mazibuko M, Khan K, Karim F, Pym AS, Maruri F, Moosa MS, van der Heijden YF, Sterling TR, Leslie A. Increased Neutrophil Count and Decreased Neutrophil CD15 Expression Correlate With TB Disease Severity and Treatment Response Irrespective of HIV Co-infection. Front Immunol. 2020 Aug 28;11:1872. doi: 10.3389/fimmu.2020.01872. PMID: 32983107; PMCID: PMC7485225
  13. Manful A, Waller L, Katz B, Cummins J, Warkentin J, Reagon B, Shaw-Kaikai J, Zhu Y, van der Heijden YF. Gaps in the care cascade for screening and treatment of refugees with tuberculosis infection in Middle Tennessee: a retrospective cohort study. BMC Infect Dis. 2020 Aug 10;20(1):592. doi: 10.1186/s12879-020-05311-0. PMID: 32778060; PMCID: PMC7418421
  14. Pettit AC, Stout JE, Belknap R, Benson CA, Séraphin MN, Lauzardo M, Horne DJ, Garfein RS, Maruri F, Ho CS; Tuberculosis Epidemiologic Studies Consortium (TBESC). Optimal testing choice and diagnostic strategies for latent tuberculosis infection among U.S.-born people living with HIV. Clin Infect Dis. 2020 Aug 6:ciaa1135. doi: 10.1093/cid/ciaa1135. Epub ahead of print. PMID: 32761083
  15. Reichler MR, Hirsch C, Yuan Y, Khan A, Dorman SE, Schluger N, Sterling TR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Predictive value of TNF-α, IFN-γ, and IL-10 for tuberculosis among recently exposed contacts in the United States and Canada. BMC Infect Dis. 2020 Jul 31;20(1):553. doi: 10.1186/s12879-020-05185-2. PMID: 32736606; PMCID: PMC7394686
  16. Weinberg A, Aaron L, Montepiedra G, Sterling TR, Browning R, Mmbaga B, Vhembo T, Naik S, Kabugho E, Masheto G, Pahwa S, Mathad JS, LaCourse SM, McCarthy K, Bradford S, Theron G, Costello D, Zimmer B, Pierre MF, Gausi K, Denti P, Haas DW, Gupta A; IMPAACT P1078 study team. Effects of Pregnancy and Isoniazid Preventive Therapy on M. tuberculosis Interferon Gamma Response Assays in Women with HIV. Clin Infect Dis. 2020 Jul 28:ciaa1083. doi: 10.1093/cid/ciaa1083. Epub ahead of print. PMID: 32720695.
  17. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Reply to Swindells et al.: Trials of Tuberculosis-Preventive Therapy in People with HIV Infection. Am J Respir Crit Care Med. 2020 Jul 15;202(2):305-306. doi: 10.1164/rccm.202003-0855LE. PMID: 32282235; PMCID: PMC7365358
  18. Oliveira-de-Souza D, Vinhaes CL, Arriaga MB, Kumar NP, Queiroz ATL, Fukutani KF, Babu S, Andrade BB. Aging increases the systemic molecular degree of inflammatory perturbation in patients with tuberculosis. Sci Rep. 2020 Jul 9;10(1):11358. doi: 10.1038/s41598-020-68255-0. PMID: 32647178; PMCID: PMC7347549
  19. Safe IP, Lacerda MVG, Printes VS, Praia Marins AF, Rebelo Rabelo AL, Costa AA, Tavares MA, Jesus JS, Souza AB, Beraldi-Magalhães F, Neves CP, Monteiro WM, Sampaio VS, Amaral EP, Gomes RS, Andrade BB, Cordeiro-Santos M. Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study). PLoS One. 2020 Jun 26;15(6):e0235381. doi: 10.1371/journal.pone.0235381. PMID: 32589648; PMCID: PMC7319340
  20. Koenig SP, Kim A, Shepherd BE, Cesar C, Veloso V, Cortes CP, Padgett D, Crabtree-Ramírez B, Gotuzzo E, McGowan CC, Sterling TR, Pape JW. Increased Mortality After Tuberculosis Treatment Completion in Persons Living With Human Immunodeficiency Virus in Latin America. Clin Infect Dis. 2020 Jun 24;71(1):215-217. doi: 10.1093/cid/ciz1032. PMID: 31629369; PMCID: PMC7312222
  21. Rebeiro PF, Cohen MJ, Ewing HM, Figueiredo MC, Peetluk LS, Andrade KB, Eakin M, Zechmeister EJ, Sterling TR. Knowledge and stigma of latent tuberculosis infection in Brazil: implications for tuberculosis prevention strategies. BMC Public Health. 2020 Jun 9;20(1):897. doi: 10.1186/s12889-020-09053-1. PMID: 32517671; PMCID: PMC7285569
  22. Kerner G, Rosain J, Guérin A, Al-Khabaz A, Oleaga-Quintas C, Rapaport F, Massaad MJ, Ding JY, Khan T, Ali FA, Rahman M, Deswarte C, Martinez-Barricarte R, Geha RS, Jeanne-Julien V, Garcia D, Chi CY, Yang R, Roynard M, Fleckenstein B, Rozenberg F, Boisson-Dupuis S, Ku CL, Seeleuthner Y, Béziat V, Marr N, Abel L, Al-Herz W, Casanova JL, Bustamante J. Inherited human IFN-γ deficiency underlies mycobacterial disease. J Clin Invest. 2020 Jun 1;130(6):3158-3171. doi: 10.1172/JCI135460. PMID: 32163377; PMCID: PMC7260033.
  23. Mehaffy C, Kruh-Garcia NA, Graham B, Jarlsberg LG, Willyerd CE, Borisov A, Sterling TR, Nahid P, Dobos KM. Identification of Mycobacterium tuberculosis Peptides in Serum Extracellular Vesicles from Persons with Latent Tuberculosis Infection. J Clin Microbiol. 2020 May 26;58(6):e00393-20. doi: 10.1128/JCM.00393-20. PMID: 32245831; PMCID: PMC7269374
  24. Penn-Nicholson A, Mbandi SK, Thompson E, Mendelsohn SC, Suliman S, Chegou NN, Malherbe ST, Darboe F, Erasmus M, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Winter J, Murphy M, Wood R, Morrow C, Van Rhijn I, Moody B, Murray M, Andrade BB, Sterling TR, Sutherland J, Naidoo K, Padayatchi N, Walzl G, Hatherill M, Zak D, Scriba TJ; Adolescent Cohort Study team; GC6-74 Consortium; SATVI Clinical and Laboratory Team; ScreenTB Consortium; AE-TBC Consortium; RePORT Brazil Team; Peruvian Household Contacts Cohort Team; CAPRISA IMPRESS team. RISK6, a 6-gene transcriptomic signature of TB disease risk, diagnosis and treatment response. Sci Rep. 2020 May 25;10(1):8629. doi: 10.1038/s41598-020-65043-8. PMID: 32451443; PMCID: PMC7248089
  25. Herricks T, Donczew M, Mast FD, Rustad T, Morrison R, Sterling TR, Sherman DR, Aitchison JD. ODELAM, rapid sequence-independent detection of drug resistance in isolates of Mycobacterium tuberculosis. Elife. 2020 May 13;9:e56613. doi: 10.7554/eLife.56613. PMID: 32401195; PMCID: PMC7263823
  26. Maruri F, Guo Y, Blackman A, van der Heijden YF, Rebeiro PF, Sterling TR. Resistance-conferring mutations on whole-genome sequencing of fluoroquinolone-resistant and -susceptible M. tuberculosis isolates: a proposed threshold for identifying resistance. Clin Infect Dis. 2020 Apr 29:ciaa496. doi: 10.1093/cid/ciaa496. Epub ahead of print. PMID: 32348473
  27. Tornheim JA, Madugundu AK, Paradkar M, Fukutani KF, Queiroz ATL, Gupte N, Gupte AN, Kinikar A, Kulkarni V, Balasubramanian U, Sreenivasamurthy S, Raja R, Pradhan N, Shivakumar SVBY, Valvi C, Hanna LE, Andrade BB, Mave V, Pandey A, Gupta A; CTRIUMPh RePORT India Study Team. Transcriptomic Profiles of Confirmed Pediatric Tuberculosis Patients and Household Contacts Identifies Active Tuberculosis, Infection, and Treatment Response Among Indian Children. J Infect Dis. 2020 Apr 27;221(10):1647-1658. doi: 10.1093/infdis/jiz639. PMID: 31796955; PMCID: PMC7184902
  28. Reichler MR, Khan A, Sterling TR, Zhao H, Chen B, Yuan Y, Moran J, McAuley J, Mangura B; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk Factors for Tuberculosis and Effect of Preventive Therapy Among Close Contacts of Persons With Infectious Tuberculosis. Clin Infect Dis. 2020 Apr 10;70(8):1562-1572. doi: 10.1093/cid/ciz438. PMID: 31127813; PMCID: PMC7011200
  29. Peetluk LS, Rebeiro PF, Cordeiro-Santos M, Kritski A, Andrade BB, Durovni B, Calvacante S, Arriaga MB, Turner MM, Figueiredo MC, Rolla VC, Sterling TR; Lack of weight gain during the first two months of treatment and HIV independently predict unsuccessful treatment outcomes in tuberculosis. Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil network. J Infect Dis. 2020 Apr 7;221(9):1416-1424. doi: 10.1093/infdis/jiz595. PMID: 31724035; PMCID: PMC7137883
  30. Araújo NCN, Cruz CMS, Arriaga MB, Cubillos-Angulo JM, Rocha MS, Silveira-Mattos PS, Matos GM, Marques IMB, Espirito Santo ICP, Almeida LL, Andrade CM, Souza LA, Netto EM, Andrade BB. Determinants of losses in the latent tuberculosis cascade of care in Brazil: A retrospective cohort study. Int J Infect Dis. 2020 Apr;93:277-283. doi: 10.1016/j.ijid.2020.02.015. Epub 2020 Feb 17. PMID: 32081776; PMCID: PMC7245517.
  31. Shivakoti R, Dalli J, Kadam D, Gaikwad S, Barthwal M, Colas RA, Mazzacuva F, Lokhande R, Dharmshale S, Bharadwaj R, Kagal A, Pradhan N, Deshmukh S, Atre S, Sahasrabudhe T, Kakrani A, Kulkarni V, Raskar S, Suryavanshi N, Chon S, Gupte A, Gupta A, Gupte N, Arriaga MB, Fukutani KF, Andrade BB, Golub JE, Mave V. Lipid mediators of inflammation and Resolution in individuals with tuberculosis and tuberculosis-Diabetes. Prostaglandins Other Lipid Mediat. 2020 Apr;147:106398. doi: 10.1016/j.prostaglandins.2019.106398. Epub 2019 Nov 11. PMID: 31726221; PMCID: PMC7067657
  32. Nacarapa E, Muchiri E, Moon TD, Charalambous S, Verdu ME, Ramos JM, Valverde EJ. Effect of Xpert MTB/RIF testing introduction and favorable outcome predictors for tuberculosis treatment among HIV infected adults in rural southern Mozambique. A retrospective cohort study. PLoS One. 2020 Mar 9;15(3):e0229995. doi: 10.1371/journal.pone.0229995. PMID: 32150595; PMCID: PMC7062249.
  33. Stout JE, Turner NA, Belknap RW, Horsburgh CR, Sterling TR, Phillips PPJ. Optimizing the Design of Latent Tuberculosis Treatment Trials: Insights from Mathematical Modeling. Am J Respir Crit Care Med. 2020 Mar 1;201(5):598-605. doi: 10.1164/rccm.201908-1606OC. PMID: 31711306
  34. Cubillos-Angulo JM, Arriaga MB, Melo MGM, Silva EC, Alvarado-Arnez LE, de Almeida AS, Moraes MO, Moreira ASR, Lapa E Silva JR, Fukutani KF, Sterling TR, Hawn TR, Kritski AL, Oliveira MM, Andrade BB. Polymorphisms in interferon pathway genes and risk of Mycobacterium tuberculosis infection in contacts of tuberculosis cases in Brazil. Int J Infect Dis. 2020 Mar;92:21-28. doi: 10.1016/j.ijid.2019.12.013. Epub 2019 Dec 13. PMID: 31843671; PMCID: PMC7197195
  35. Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial. Contemp Clin Trials. 2020 Mar;90:105938. doi: 10.1016/j.cct.2020.105938. Epub 2020 Jan 22. PMID: 31981713; PMCID: PMC7307310
  36. Barreda NN, Arriaga MB, Aliaga JG, Lopez K, Sanabria OM, Carmo TA, Fróes Neto JF, Lecca L, Andrade BB, Calderon RI. Severe pulmonary radiological manifestations are associated with a distinct biochemical profile in blood of tuberculosis patients with dysglycemia. BMC Infect Dis. 2020 Feb 14;20(1):139. doi: 10.1186/s12879-020-4843-0. PMID: 32059707; PMCID: PMC7023734
  37. Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR Jr, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. doi: 10.15585/mmwr.rr6901a1. PMID: 32053584; PMCID: PMC7041302
  38. Humphrey JM, Mpofu P, Pettit AC, Musick B, Carter EJ, Messou E, Marcy O, Crabtree-Ramirez B, Yotebieng M, Anastos K, Sterling TR, Yiannoutsos C, Diero L, Wools-Kaloustian K. Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. Open Forum Infect Dis. 2020 Jan 10;7(1):ofaa006. doi: 10.1093/ofid/ofaa006. PMID: 32010735; PMCID: PMC6984675



  1. Arriaga MB, Torres NMC, Araujo NCN, Caldas SCC, Andrade BB, Netto EM. Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study. PLoS One. 2019 Dec 26;14(12):e0227101. doi: 10.1371/journal.pone.0227101. PMID: 31877199; PMCID: PMC6932797
  2. Pettit AC, Jenkins CA, Blevins Peratikos M, Yotebieng M, Diero L, Do CD, Ross J, Veloso VG, Hawerlander D, Marcy O, Shepherd BE, Fenner L, Sterling TR; International Epidemiology Databases to Evaluate AIDS (IeDEA) Consortium. Directly observed therapy and risk of unfavourable tuberculosis treatment outcomes among an international cohort of people living with HIV in low- and middle-income countries. J Int AIDS Soc. 2019 Dec;22(12):e25423. doi: 10.1002/jia2.25423. PMID: 31814312; PMCID: PMC6900483
  3. Huaman MA, Sterling TR. Treatment of Latent Tuberculosis Infection-An Update. Clin Chest Med. 2019 Dec;40(4):839-848. doi: 10.1016/j.ccm.2019.07.008. PMID: 31731988; PMCID: PMC7043866
  4. Albuquerque VVS, Kumar NP, Fukutani KF, Vasconcelos B, Arriaga MB, Silveira-Mattos PS, Babu S, Andrade BB. Plasma levels of C-reactive protein, matrix metalloproteinase-7 and lipopolysaccharide-binding protein distinguish active pulmonary or extrapulmonary tuberculosis from uninfected controls in children. Cytokine. 2019 Nov;123:154773. doi: 10.1016/j.cyto.2019.154773. Epub 2019 Jul 9. PMID: 31299414
  5. Vinhaes CL, Oliveira-de-Souza D, Silveira-Mattos PS, Nogueira B, Shi R, Wei W, Yuan X, Zhang G, Cai Y, Barry CE 3rd, Via LE, Fukutani KF, Andrade BB, Mayer-Barber KD. Changes in inflammatory protein and lipid mediator profiles persist after antitubercular treatment of pulmonary and extrapulmonary tuberculosis: A prospective cohort study. Cytokine. 2019 Nov;123:154759. doi: 10.1016/j.cyto.2019.154759. Epub 2019 Jun 18. PMID: 31226436; PMCID: PMC6739167
  6. Gibson EG, Oviatt AA, Cacho M, Neuman KC, Chan PF, Osheroff N. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV. Biochemistry. 2019 Nov 5;58(44):4447-4455. doi: 10.1021/acs.biochem.9b00805. Epub 2019 Oct 28. PMID: 31617352; PMCID: PMC7450530
  7. Moon TD, Nacarapa E, Verdu ME, Macuácua S, Mugabe D, Gong W, Carlucci JG, Ramos JM, Valverde E. Tuberculosis Treatment Outcomes Among Children in Rural Southern Mozambique: A 12-year Retrospective Study. Pediatr Infect Dis J. 2019 Oct;38(10):999-1004. doi: 10.1097/INF.0000000000002435. PMID: 31568138; PMCID: PMC6776242
  8. Zürcher K, Ballif M, Kiertiburanakul S, Chenal H, Yotebieng M, Grinsztejn B, Michael D, Sterling TR, Ngonyani KM, Mandalakas AM, Egger M, Pettit AC, Fenner L; International Epidemiology Databases to Evaluate AIDS (IeDEA) consortium. Diagnosis and clinical outcomes of extrapulmonary tuberculosis in antiretroviral therapy programmes in low- and middle-income countries: a multicohort study. J Int AIDS Soc. 2019 Sep;22(9):e25392. doi: 10.1002/jia2.25392. PMID: 31507083; PMCID: PMC6737289
  9. van der Heijden YF, Hughes J, Dowdy DW, Streicher E, Chihota V, Jacobson KR, Warren R, Theron G. Overcoming limitations of tuberculosis information systems: researcher and clinician perspectives. Public Health Action. 2019 Sep 21;9(3):120-127. doi: 10.5588/pha.19.0014. PMID: 31803584; PMCID: PMC6827492
  10. Stout JE, Sterling TR, Horsburgh CR Jr. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019 Sep 12;381(11):e23. doi: 10.1056/NEJMc1908492. PMID: 31509689.
  11. Calderon RI, Arriaga MB, Lopez K, Barreda NN, Sanabria OM, Fróes Neto JF, Araújo DN, Lecca L, Andrade BB. High prevalence and heterogeneity of Dysglycemia in patients with tuberculosis from Peru: a prospective cohort study. BMC Infect Dis. 2019 Sep 11;19(1):799. doi: 10.1186/s12879-019-4416-2. PMID: 31510930; PMCID: PMC6737721
  12. Cubillos-Angulo JM, Arriaga MB, Silva EC, Müller BLA, Ramalho DMP, Fukutani KF, Miranda PFC, Moreira ASR, Ruffino-Netto A, Lapa E Silva JR, Sterling TR, Kritski AL, Oliveira MM, Andrade BB. Polymorphisms in TLR4 and TNFA and Risk of Mycobacterium tuberculosis Infection and Development of Active Disease in Contacts of Tuberculosis Cases in Brazil: A Prospective Cohort Study. Clin Infect Dis. 2019 Aug 30;69(6):1027-1035. doi: 10.1093/cid/ciy1001. PMID: 30481307; PMCID: PMC6735688
  13. Schutz C, Barr D, Andrade BB, Shey M, Ward A, Janssen S, Burton R, Wilkinson KA, Sossen B, Fukutani KF, Nicol M, Maartens G, Wilkinson RJ, Meintjes G. Clinical, microbiologic, and immunologic determinants of mortality in hospitalized patients with HIV-associated tuberculosis: A prospective cohort study. PLoS Med. 2019 Jul 5;16(7):e1002840. doi: 10.1371/journal.pmed.1002840. PMID: 31276515; PMCID: PMC6611568.
  14. Kumar NP, Fukutani KF, Shruthi BS, Alves T, Silveira-Mattos PS, Rocha MS, West K, Natarajan M, Viswanathan V, Babu S, Andrade BB, Kornfeld H. Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity. Elife. 2019 Jul 4;8:e46477. doi: 10.7554/eLife.46477. PMID: 31271354; PMCID: PMC6660216
  15. Narendran G, Oliveira-de-Souza D, Vinhaes CL, Akrami K, Fukutani KF, Banu K, Chandrasekaran P, Ravichandran N, Sereti I, Swaminathan S, Andrade BB. Multifocal tuberculosis-associated immune reconstitution inflammatory syndrome - a case report of a complicated scenario. BMC Infect Dis. 2019 Jun 17;19(1):529. doi: 10.1186/s12879-019-4182-1. PMID: 31208430; PMCID: PMC6580602
  16. Demitto FO, Schmaltz CAS, Sant'Anna FM, Arriaga MB, Andrade BB, Rolla VC. Predictors of early mortality and effectiveness of antiretroviral therapy in TB-HIV patients from Brazil. PLoS One. 2019 Jun 6;14(6):e0217014. doi: 10.1371/journal.pone.0217014. PMID: 31170171; PMCID: PMC6553696
  17. Oliveira-de-Souza D, Vinhaes CL, Arriaga MB, Kumar NP, Cubillos-Angulo JM, Shi R, Wei W, Yuan X, Zhang G, Cai Y, Barry CE 3rd, Via LE, Sher A, Babu S, Mayer-Barber KD, Nakaya HI, Fukutani KF, Andrade BB. Molecular degree of perturbation of plasma inflammatory markers associated with tuberculosis reveals distinct disease profiles between Indian and Chinese populations. Sci Rep. 2019 May 29;9(1):8002. doi: 10.1038/s41598-019-44513-8. PMID: 31142816; PMCID: PMC6541651
  18. Fiske CT, Blackman A, Maruri F, Rebeiro PF, Huaman M, Kator J, Scott Algood HM, Sterling TR. Increased vitamin D receptor expression from macrophages after stimulation with M. tuberculosis among persons who have recovered from extrapulmonary tuberculosis. BMC Infect Dis. 2019 Apr 30;19(1):366. doi: 10.1186/s12879-019-3958-7. PMID: 31039752; PMCID: PMC6492421
  19. Khan PY, Yates TA, Osman M, Warren RM, van der Heijden Y, Padayatchi N, Nardell EA, Moore D, Mathema B, Gandhi N, Eldholm V, Dheda K, Hesseling AC, Mizrahi V, Rustomjee R, Pym A. Transmission of drug-resistant tuberculosis in HIV-endemic settings. Lancet Infect Dis. 2019 Mar;19(3):e77-e88. Epub 2018 Dec 13. Review. Erratum in: Lancet Infect Dis. 2019 Mar 6. PMID: 30554996
  20. Crabtree-Ramírez B, Jenkins C, Jayathilake K, Carriquiry G, Veloso V, Padgett D, Gotuzzo E, Cortes C, Mejia F, McGowan CC, Duda S, Shepherd BE, Sterling TR. HIV-related tuberculosis: mortality risk in persons without vs. with culture-confirmed disease. Int J Tuberc Lung Dis. 2019 Mar 1;23(3):306-314. doi: 10.5588/ijtld.18.0111. PMID: 30871661; PMCID: PMC6537600
  21. Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, van der Heijden Y, Wood R, Rustomjee R, Kana BD. Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. Lancet Infect Dis. 2019 Mar;19(3):e65-e76. doi: 10.1016/S1473-3099(18)30477-8. Epub 2018 Dec 13. PMID: 30554995; PMCID: PMC6401310
  22. Amaral EP, Costa DL, Namasivayam S, Riteau N, Kamenyeva O, Mittereder L, Mayer-Barber KD, Andrade BB, Sher A. A major role for ferroptosis in Mycobacterium tuberculosis-induced cell death and tissue necrosis. J Exp Med. 2019 Mar 4;216(3):556-570. doi: 10.1084/jem.20181776. Epub 2019 Feb 20. PMID: 30787033; PMCID: PMC6400546
  23. Silveira-Mattos PS, Narendran G, Akrami K, Fukutani KF, Anbalagan S, Nayak K, Subramanyam S, Subramani R, Vinhaes CL, Souza DO, Antonelli LR, Satagopan K, Porter BO, Sher A, Swaminathan S, Sereti I, Andrade BB. Differential expression of CXCR3 and CCR6 on CD4+ T-lymphocytes with distinct memory phenotypes characterizes tuberculosis-associated immune reconstitution inflammatory syndrome. Sci Rep. 2019 Feb 6;9(1):1502. doi: 10.1038/s41598-018-37846-3. Erratum in: Sci Rep. 2019 May 24;9(1):8036. PMID: 30728405; PMCID: PMC6365576
  24. Gil-Santana L, Cruz LAB, Arriaga MB, Miranda PFC, Fukutani KF, Silveira-Mattos PS, Silva EC, Oliveira MG, Mesquita EDD, Rauwerdink A, Cobelens F, Oliveira MM, Kritski A, Andrade BB. Tuberculosis-associated anemia is linked to a distinct inflammatory profile that persists after initiation of antitubercular therapy. Sci Rep. 2019 Feb 4;9(1):1381. doi: 10.1038/s41598-018-37860-5. PMID: 30718725; PMCID: PMC6361962
  25. Ragheb MN, Thomason MK, Hsu C, Nugent P, Gage J, Samadpour AN, Kariisa A, Merrikh CN, Miller SI, Sherman DR, Merrikh H. Inhibiting the Evolution of Antibiotic Resistance. Mol Cell. 2019 Jan 3;73(1):157-165.e5. doi: 10.1016/j.molcel.2018.10.015. Epub 2018 Nov 15. PMID: 30449724; PMCID: PMC6320318.



  1. van der Heijden YF, Abdullah F, Andrade BB, Andrews JR, Christopher DJ, Croda J, Ewing H, Haas DW, Hatherill M, Horsburgh CR Jr, Mave V, Nakaya HI, Rolla V, Srinivasan S, Sugiyono RI, Ugarte-Gil C, Hamilton C. Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting. Tuberculosis (Edinb). 2018 Dec;113:153-162. doi: 10.1016/ Epub 2018 Oct 1. PMID: 30514497; PMCID: PMC6349374
  2. Pettit AC, Shepherd BE, Sterling TR. Treatment of drug-susceptible tuberculosis among people living with human immunodeficiency virus infection: an update. Curr Opin HIV AIDS. 2018 Nov;13(6):469-477. doi: 10.1097/COH.0000000000000506. PMID: 30222609; PMCID: PMC6389504
  3. Stout JE, Wu Y, Ho CS, Pettit AC, Feng PJ, Katz DJ, Ghosh S, Venkatappa T, Luo R; Tuberculosis Epidemiologic Studies Consortium. Evaluating latent tuberculosis infection diagnostics using latent class analysis. Thorax. 2018 Nov;73(11):1062-1070. doi: 10.1136/thoraxjnl-2018-211715. Epub 2018 Jul 7. PMID: 29982223; PMCID: PMC6494673
  4. Huaman MA, Henson D, Rondan PL, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Ticona C, Abarca S, Heredia P, Aguirre A, Sterling TR, Garvy BA, Fichtenbaum CJ. Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru. PLoS One. 2018 Sep 13;13(9):e0202191. PMID: 30212453, PMCID: PMC6136705
  5. Reichler MR, Khan A, Sterling TR, Zhao H, Moran J, McAuley J, Bessler P, Mangura B; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk and Timing of Tuberculosis Among Close Contacts of Persons with Infectious Tuberculosis. J Infect Dis. 2018 Aug 14;218(6):1000-1008. doi: 10.1093/infdis/jiy265. PMID: 29767733; PMCID: PMC6534268
  6. Gibson EG, Blower TR, Cacho M, Bax B, Berger JM, Osheroff N. Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons. ACS Infect Dis. 2018 Aug 10;4(8):1211-1222. doi: 10.1021/acsinfecdis.8b00035. Epub 2018 May 17. PMID: 29746087; PMCID: PMC6309371.
  7. van der Heijden YF, Karim F, Chinappa T, Mufamadi G, Zako L, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS. Older age at first tuberculosis diagnosis is associated with tuberculosis recurrence in HIV-negative persons. Int J Tuberc Lung Dis. 2018 Aug 1;22(8):871-877. PMID: 29991395, PMCID: PMC6064608
  8. Amaral EP, Riteau N, Moayeri M, Maier N, Mayer-Barber KD, Pereira RM, Lage SL, Kubler A, Bishai WR, D'Império-Lima MR, Sher A, Andrade BB. Lysosomal Cathepsin Release Is Required for NLRP3-Inflammasome Activation by Mycobacterium tuberculosis in Infected Macrophages. Front Immunol. 2018 Jun 21;9:1427. PMID: 29977244, PMCID: PMC6021483
  9. Moro RN, Scott NA, Vernon A, Tepper NK, Goldberg SV, Schwartzman K, Leung CC, Schluger NW, Belknap RW, Chaisson RE, Narita M, Machado ES, Lopez M, Sanchez J, Villarino ME, Sterling TR. Exposure to Latent Tuberculosis Treatment during Pregnancy. The PREVENT TB and the iAdhere Trials. Ann Am Thorac Soc. 2018 May;15(5):570-580. doi: 10.1513/AnnalsATS.201704-326OC. PMID: 29393655; PMCID: PMC6624829.
  10. Huaman MA, Ticona E, Miranda G, Kryscio RJ, Mugruza R, Aranda E, Rondan P, Henson D, Ticona C, Sterling TR, Fichtenbaum C, Garvy BA. The Relationship between Latent Tuberculosis Infection and Acute Myocardial Infarction. Clin Infect Dis. 2018 Mar 5;66(6):886-892. PMID: 29069328, PMCID:PMC5850031
  11. Ramírez S, Mejía F, Rojas M, Seas C, Van der Stuyft P, Gotuzzo E, Otero L. HIV screening among newly diagnosed TB patients: a cross sectional study in Lima, Peru. BMC Infect Dis. 2018 Mar 20;18(1):136. PMID: 29558891, PMCID: PMC5861614
  12. Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, Chaturvedi N, Srinivasan S, Johnson DH, Bishai WR. Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. Lancet Infect Dis. 2018 Mar;18(3):e64-e75. doi: 10.1016/S1473-3099(17)30623-0. Epub 2017 Oct 27. PMID: 29111156
  13. Pettit AC, Giganti MJ, Ingle SM, May MT, Shepherd BE, Gill MJ, Fätkenheuer G, Abgrall S, Saag MS, Del Amo J, Justice AC, Miro JM, Cavasinni M, Dabis F, Monforte AD, Reiss P, Guest J, Moore D, Shepherd L, Obel N, Crane HM, Smith C, Teira R, Zangerle R, Sterne JA, Sterling TR; Antiretroviral Therapy Cohort Collaboration (ART-CC) investigators. Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation. J Int AIDS Soc. 2018 Jan;21(1). PMID: 29334197, PMCID: PMC5810321
  14. Hussain S, Hasnain J, Hussain Z, Badshah M, Siddique H, Fiske C, Pettit A. Type of Treatment Supporters in Successful Completion of Tuberculosis Treatment: A Retrospective Cohort Study in Pakistan. Open Infect Dis J. 2018;10:37-42. PMID: 30008966, PMCID: PMC6044441
  15. Grifoni A, Sidney J, Carpenter C, Phillips E, Mallal S, Scriba TJ, Sette A, Lindestam Arlehamn CS. Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 159 individuals from the Worcester region of the Western Cape province of South Africa. Hum Immunol. 2018 Mar;79(3):143-144. PMID: 29398200.


  1. Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, Wright A, Chen MP, Moro RN, Scott NA, Arevalo B, Miró JM, Villarino ME, Weiner M, Borisov AS; TB Trials Consortium iAdhere Study Team. Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection: A Randomized Trial. Ann Intern Med. 2017 Nov 21;167(10):689-697. doi: 10.7326/M17-1150. Epub 2017 Nov 7. PMID: 29114781; PMCID: PMC5766341
  2. Ashley RE, Blower TR, Berger JM, Osheroff N. Recognition of DNA Supercoil Geometry by Mycobacterium tuberculosis Gyrase. Biochemistry. 2017 Oct 10;56(40):5440-5448. Epub 2017 Sep 25. PMCID: PMC5637011
  3. Bourgi K, Fiske C, Sterling TR. Tuberculosis Meningitis. Curr Infect Dis Rep. 2017 Sep 11;19(11):39. doi: 10.1007/s11908-017-0595-4. PMID: 28895024
  4. Carlucci JG, Blevins Peratikos M, Kipp AM, Lindegren ML, Du QT, Renner L, Reubenson G, Ssali J, Yotebieng M, Mandalakas AM, Davies MA, Ballif M, Fenner L, Pettit AC; International Epidemiology Databases to Evaluate AIDS (IeDEA) Network. Tuberculosis Treatment Outcomes Among HIV/TB-Coinfected Children in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Network. J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):156-163. doi: 10.1097/QAI.0000000000001335. PMID: 28234689; PMCID: PMC5429189
  5. van der Heijden YF, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa. Int J Tuberc Lung Dis. 2017 Jun 1;21(6):670-676. PMCID: PMC5536436
  6. Prada-Medina CA, Fukutani KF, Pavan Kumar N, Gil-Santana L, Babu S, Lichtenstein F, West K, Sivakumar S, Menon PA, Viswanathan V, Andrade BB, Nakaya HI, Kornfeld H. Systems Immunology of Diabetes-Tuberculosis Comorbidity Reveals Signatures of Disease Complications. Sci Rep. 2017 May 17;7(1):1999. PMCID: PMC5435727
  7. Rockwood N, Costa DL, Amaral EP, Bruyn ED, Kubler A, Gil-Santana L, Fukutani KF, Scanga CA, Flynn JL, Jackson SH, Wilkinson KA, Bishai WR, Sher A, Wilkinson RJ, Andrade BB. Mycobacterium tuberculosis induction of heme oxygenase-1 expression is dependent on oxidative stress and reflects treatment outcomes. Front Immunol. 2017 May 12. PMCID: PMC5427075
  8. Huaman MA, Kryscio RJ, Fichtenbaum CJ, Henson D, Salt E, Sterling TR, Garvy BA. Tuberculosis and risk of acute myocardial infarction: a propensity score-matched analysis. Epidemiol Infect. 2017 May;145(7):1363-1367. doi: 10.1017/S0950268817000279. Epub 2017 Feb 16. PMID: 28202093; PMCID: PMC5616129
  9. Bordelon H, Ricks KM, Pask ME, Russ PK, Solinas F, Baglia ML, Short PA, Nel A, Blackburn J, Dheda K, Zamudio C, Cáceres T, Wright DW, Haselton FR, Pettit AC. Design and use of mouse control DNA for DNA biomarker extraction and PCR detection from urine: Application for transrenal Mycobacterium tuberculosis DNA detection. J Microbiol Methods. 2017 May;136:65-70. doi: 10.1016/j.mimet.2017.02.010. Epub 2017 Mar 9. PMID: 28285168; PMCID: PMC5421388
  10. Otero L, Villegas L, Huamán M, Sterling T, Seas C. The need for randomised controlled trials of isoniazid monoresistant tuberculosis treatment. Lancet Infect Dis. 2017 Apr;17(4):363-364. doi: 10.1016/S1473-3099(17)30121-4. PMID: 28346171
  11. Miranda P, Gil-Santana L, Oliveira MG, Mesquita ED, Silva E, Rauwerdink A, Cobelens F, Oliveira MM, Andrade BB, Kritski A. Sustained elevated levels of C-reactive protein and ferritin in pulmonary tuberculosis patients remaining culture positive upon treatment initiation. PLoS One. 2017 Apr 6;12(4):e0175278. doi: 10.1371/journal.pone.0175278. PMID: 28384354; PMCID: PMC5383283
  12. Ellis H, Mulder C, Valverde E, Poling A, Edwards T. Reproducibility of African giant pouched rats detecting Mycobacterium tuberculosis. BMC Infect Dis. 2017 Apr 24;17(1):298. doi: 10.1186/s12879-017-2347-3. PMID: 28438117; PMCID: PMC5402322
  13. Moro RN, Sterling TR, Saukkonen J, Vernon A, Horsburgh CR, Chaisson RE, Hamilton CD, Villarino ME, Goldberg S. Factors associated with non-completion of follow-up: 33-month latent tuberculous infection treatment trial. Int J Tuberc Lung Dis. 2017 Mar 1;21(3):286-296. doi: 10.5588/ijtld.16.0469. Epub 2017 Jan 13. PMID: 28087928; PMCID: PMC6563818
  14. McAnaw SE, Hesseling AC, Seddon JA, Dooley KE, Garcia-Prats AJ, Kim S, Jenkins HE, Schaaf HS, Sterling TR, Horsburgh CR. Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities. Int J Infect Dis. 2017 Mar;56:194-199. doi: 10.1016/j.ijid.2016.11.423. Epub 2016 Dec 9. PMID: 27955992; PMCID: PMC5606236
  15. Clouse K, Blevins M, Lindegren ML, Yotebieng M, Nguyen DT, Omondi A, Michael D, Zannou DM, Carriquiry G, Pettit A; International Epidemiologic Databases to Evaluate AIDS (IeDEA) collaboration. Low implementation of Xpert MTB/RIF among HIV/TB co-infected adults in the International epidemiologic Databases to Evaluate AIDS (IeDEA) program. PLoS One. 2017 Feb 9;12(2):e0171384. doi: 10.1371/journal.pone.0171384. PMID: 28182705; PMCID: PMC5300213
  16. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM, Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M, Shinnick TM, Sterling TR, Warshauer DM, Woods GL. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan 15;64(2):111-115. doi: 10.1093/cid/ciw778. PMID: 28052967; PMCID: PMC5504475
  17. Manion M, Andrade BB, DerSimonian R, Gu W, Rupert A, Musselwhite LW, Sierra-Madero JG, Belaunzaran-Zamudio PF, Sanne I, Lederman MM, Sereti I. Country of residence is associated with distinct inflammatory biomarker signatures in HIV-infected patients. J Virus Erad. 2017 Jan 1;3(1):24-33. PMID: 28275455; PMCID: PMC5337418
  18. Geadas C, Stoszek SK, Sherman D, Andrade BB, Srinivasan S, Hamilton CD, Ellner J. Advances in basic and translational tuberculosis research: Proceedings of the first meeting of RePORT international. Tuberculosis (Edinb). 2017 Jan;102:55-67. doi: 10.1016/ Epub 2016 Nov 27. PMID: 28061953
  19. Arlehamn CS, Copin R, Leary S, Mack SJ, Phillips E, Mallal S, Sette A, Blatner G, Siefers H, Ernst JD; TBRU-ASTRa Study Team. Sequence-based HLA-A, B, C, DP, DQ, and DR typing of 100 Luo infants from the Boro area of Nyanza Province, Kenya. Hum Immunol. 2017 Apr;78(4):325-326. Epub 2017 Mar 16. PMID: 28315719; PMCID: PMC5519768
  20. Pavlos R, Redwood A, Phillips E. AdDRESSing T-cell responses to antituberculous drugs. Br J Dermatol. 2017 Feb;176(2):292-293. PMID: 28244076; PMCID: PMC5429398
  21. Gelbard A, Katsantonis NG, Mizuta M, Newcomb D, Rotsinger J, Rousseau B, Daniero JJ, Edell ES, Ekbom DC, Kasperbauer JL, Hillel AT, Yang L, Garrett CG, Netterville JL, Wootten CT, Francis DO, Stratton C, Jenkins K, McGregor TL, Gaddy JA, Blackwell TS, Drake WP. Molecular analysis of idiopathic subglottic stenosis for Mycobacterium species. Laryngoscope. 2017 Jan;127(1):179-185. doi: 10.1002/lary.26097. Epub 2016 Jun 14. PMID: 27295947; PMCID: PMC5156582
  22. Carvalho ES, de Souza AW, Leão SC, Levy-Neto M, de Oliveira RS, Drake W, de Franco MF, Saldiva PH, Gutierrez PS, Andrade LE. Absence of mycobacterial DNA in peripheral blood and artery specimens in patients with Takayasu arteritis. Clin Rheumatol. 2017 Jan;36(1):205-208. doi: 10.1007/s10067-016-3400-0. Epub 2016 Sep 7. PMID: 27604701; PMCID: PMC5742422


  1. Sterling TR. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016 Dec 1;20(12):42-47. PMID: 28240572
  2. Eilertson B, Maruri F, Blackman A, Herrera M, Sterling TR. Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2016 Sep;20(9):1276-7. PMID: 27510259.
  3. Eilertson B, Maruri F, Blackman A, Guo Y, Herrera M, van der Heijden Y, Shyr Y, Sterling TR. A novel resistance mutation in eccC5 of the ESX-5 secretion system confers ofloxacin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2016 Sep;71(9):2419-27. PMCID: PMC4992850
  4. Buchacz K, Lau B, Jing Y, Bosch R, Abraham AG, Gill MJ, Silverberg MJ, Goedert JJ, Sterling TR, Althoff KN, Martin JN, Burkholder G, Gandhi N, Samji H, Patel P, Rachlis A, Thorne JE, Napravnik S, Henry K, Mayor A, Gebo K, Gange SJ, Moore RD, Brooks JT; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. J Infect Dis. 2016 Sep 15;214(6):862-72. PMID: 27559122
  5. Russ PK, Karhade AV, Bitting AL, Doyle A, Solinas F, Wright DW, Haselton FR. A Prototype Biomarker Detector Combining Biomarker Extraction and Fixed Temperature PCR. J Lab Autom. 2016 Aug;21(4):590-8. doi: 10.1177/2211068216634072. Epub 2016 Feb 26. PMID: 26920577
  6. Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, Dowdy D, Gill J, Rachlis A, Moore R, Sterling TR; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) investigators of International epidemiologic Databases to Evaluate AIDS (IeDEA). Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):572-8. PMCID: PMC4942351
  7. Edwards TL, Valverde E, Mulder C, Cox C, Poling A. Pouched rats as detectors of tuberculosis: comparison to concentrated smear microscopy. Eur Respir J. 2016 Aug;48(2):579-82. doi: 10.1183/13993003.00264-2016. Epub 2016 Jun 10. PMID: 27288036
  8. Rotsinger JE, Celada LJ, Polosukhin VV, Atkinson JB, Drake WP. Molecular Analysis of Sarcoidosis Granulomas Reveals Antimicrobial Targets. Am J Respir Cell Mol Biol. 2016 Jul;55(1):128-34. doi: 10.1165/rcmb.2015-0212OC. PMID: 26807608; PMCID: PMC4942207
  9. Sterling TR, Scott NA, Miro JM, Calvet G, La Rosa A, Infante R, Chen MP, Benator DA, Gordin F, Benson CA, Chaisson RE, Villarino ME; Tuberculosis Trials Consortium, the AIDS Clinical Trials Group for the PREVENT TB Trial (TBTC Study 26ACTG 5259) The investigators of the TB Trials Consortium and the AIDS Clinical Trials Group for the PREVENT TB Trial are listed in the Supplement, item 17. Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons. AIDS. 2016 Jun 19;30(10):1607-15. doi: 10.1097/QAD.0000000000001098. PMID: 27243774; PMCID: PMC4899978
  10. Moro RN, Borisov AS, Saukkonen J, Khan A, Sterling TR, Villarino ME, Scott NA, Shang N, Kerrigan A, Goldberg SV. Factors Associated With Noncompletion of Latent Tuberculosis Infection Treatment: Experience From the PREVENT TB Trial in the United States and Canada. Clin Infect Dis. 2016 Jun 1;62(11):1390-1400. doi: 10.1093/cid/ciw126. Epub 2016 Mar 6. PMID: 26951571; PMCID: PMC6521957
  11. Charles MK, Lindegren ML, Wester CW, Blevins M, Sterling TR, Dung NT, Dusingize JC, Avit-Edi D, Durier N, Castelnuovo B, Nakigozi G, Cortes CP, Ballif M, Fenner L; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration. Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. PLoS One. 2016 Apr 13;11(4):e0153243. PMCID: PMC4830552
  12. Villegas L, Otero L, Sterling TR, Huaman MA, Van der Stuyft P, Gotuzzo E, Seas C. Prevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, Peru. PLoS One. 2016 Apr 5;11(4):e0152933. PMCID: PMC4821555
  13. Aldred KJ, Blower TR, Kerns RJ, Berger JM, Osheroff N. Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E839-46. doi: 10.1073/pnas.1525055113. Epub 2016 Jan 20. PMID: 26792518; PMCID: PMC4763725
  14. Metushi I, Uetrecht J, Phillips E. Mechanism of isoniazid-induced hepatotoxicity: then and now. Br J Clin Pharmacol. 2016 Jun;81(6):1030-6. Epub 2016 Feb 25. PMID: 26773235; PMCID: PMC4876174.


  1. Huaman MA, Henson D, Ticona E, Sterling TR, Garvy BA. Tuberculosis and Cardiovascular Disease: Linking the Epidemics. Trop Dis Travel Med Vaccines. 2015;1. pii: 10. Epub 2015 Oct 30. PMCID: PMC4729377.
  2. Hamilton CD, Swaminathan S, Christopher DJ, Ellner J, Gupta A, Sterling TR, Rolla V, Srinivasan S, Karyana M, Siddiqui S, Stoszek SK, Kim P. RePORT International: Advancing Tuberculosis Biomarker Research Through Global Collaboration. Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S155-9. doi: 10.1093/cid/civ611. PMID: 26409277; PMCID: PMC4583572
  3. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, Grant AD, Grzemska M, Harris R, Horsburgh CR Jr, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, Van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015 Sep 24. pii: ERJ-01245-2015. PMID:26405286
  4. Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI. Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829. PMID: 26260821; PMCID: PMC5080618
  5. Sterling TR. Four-month fluoroquinolone-containing regimens are inferior to standard 6-month tuberculosis treatment. Evid Based Med. 2015 Aug;20(4):128-9. PMID: 25926523
  6. Sterling TR, Moro RN, Borisov AS, Phillips E, Shepherd G, Adkinson NF, Weis S, Ho C, Villarino ME; Tuberculosis Trials Consortium. Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. Clin Infect Dis. 2015 Aug 15;61(4):527-35. doi: 10.1093/cid/civ323. Epub 2015 Apr 22. PMID: 25904367; PMCID: PMC4560029.
  7. Creecy A, Russ PK, Solinas F, Wright DW, Haselton FR. Tuberculosis Biomarker Extraction and Isothermal Amplification in an Integrated Diagnostic Device. PLoS One. 2015 Jul 1;10(7):e0130260. doi: 10.1371/journal.pone.0130260. PMID: 26132307; PMCID: PMC4488445
  8. Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW; Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15;60(12):1860-3. doi: 10.1093/cid/civ155. Epub 2015 Feb 26. PMID: 25722197; PMCID: PMC4542662
  9. van der Heijden YF, Heerman WJ, McFadden S, Zhu Y, Patterson, B. (2015). Missed Opportunities for Tuberculosis Screening in Primary Care. Journal of Pediatrics. 2015 May; 166(5): 1240-5. PMCID: PMC4414729
  10. van der Heijden YF, Maruri F, Holt E, Mitchel E, Warkentin J, Sterling TR. (2015). A Comparison of Interview Methods to Ascertain Fluoroquinolone Exposure Before Tuberculosis Diagnosis. Epidemiology and Infection. 2015 Apr; 143(5), 960-5. PMCID: PMC4352378
  11. Huaman MA, Fiske CT, Jones TF, Warkentin J, Shepherd BE, Ingram LA, Maruri F, Sterling TR. Tuberculosis and the risk of infection with other intracellular bacteria: a population-based study. Epidemiol Infect. 2015 Apr;143(5):951-9. PMCID: PMC4336842
  12. Ballif M, Renner L, Claude Dusingize J, Leroy V, Ayaya S, Wools-Kaloustian K, Cortes CP, McGowan CC, Graber C, Mandalakas AM, Mofenson LM, Egger M, Kumara Wati KD, Nallusamy R, Reubenson G, Davies MA, Fenner L; International Epidemiologic Databases to Evaluate AIDS (IeDEA); International Epidemiologic Databases to Evaluate AIDS IeDEA. Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. J Pediatric Infect Dis Soc. 2015 Mar;4(1):30-8. doi: 10.1093/jpids/piu020. Epub 2014 Mar 28. PMID: 26407355; PMCID: PMC5654358
  13. Villarino ME, Scott NA, Weis SE, Weiner M, Conde MB, Jones B, Nachman S, Oliveira R, Moro RN, Shang N, Goldberg SV, Sterling TR; International Maternal Pediatric and Adolescents AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid. JAMA Pediatr. 2015 Mar;169(3):247-55. doi: 10.1001/jamapediatrics.2014.3158. Erratum in: JAMA Pediatr. 2015 Sep;169(9):878. PMID: 25580725; PMCID: PMC6624831
  14. Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H; TSHEPISO Study Team. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis. 2015 Jan 15;211(2):197-205. doi: 10.1093/infdis/jiu429. Epub 2014 Jul 31. Erratum in: J Infect Dis. 2015 Jul 1;212(1):169. PMID: 25081933; PMCID: PMC4334832
  15. Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team. Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers. Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30. PMID: 25824215; PMCID: PMC4432148


  1. Ballif M, Nhandu V, Wood R, Dusingize JC, Carter EJ, Cortes CP, McGowan CC, Diero L, Graber C, Renner L, Hawerlander D, Kiertiburanakul S, Du QT, Sterling TR, Egger M, Fenner L; International epidemiological Databases to Evaluate AIDS (IeDEA). Detection and management of drug-resistant tuberculosis in HIV-infected patients in lower-income countries. Int J Tuberc Lung Dis. 2014 Nov;18(11):1327-36. doi: 10.5588/ijtld.14.0106. PMID: 25299866; PMCID: PMC4323497
  2. Menzies D, Sterling TR. Treatment of Mycobacterium tuberculosis infection: time to get a move on? Ann Intern Med. 2014 Sep 16;161(6):449-50. PMID: 25111391
  3. Eilertson B, Maruri F, Blackman A, Herrera M, Samuels DC, Sterling TR. High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother. 2014 Jun;58(6):3270-5. doi: 10.1128/AAC.02066-13. Epub 2014 Mar 31. PMID: 24687490; PMCID: PMC4068501
  4. Weiner M, Savic RM, Kenzie WR, Wing D, Peloquin CA, Engle M, Bliven E, Prihoda TJ, Gelfond JA, Scott NA, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME; Tuberculosis Trials Consortium PREVENT TB Pharmacokinetic Group. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly With Rifapentine and Isoniazid for Latent Tuberculosis Infection. J Pediatric Infect Dis Soc. 2014 Jun;3(2):132-45. doi: 10.1093/jpids/pit077. Epub 2014 Jan 16. PMID: 26625366.
  5. Fiske CT, Yan FX, Hirsch-Moverman Y, Sterling TR, Reichler MR; Tuberculosis Epidemiologic Studies Consortium Task Order 2 Team. Risk factors for treatment default in close contacts with latent tuberculous infection. Int J Tuberc Lung Dis. 2014 Apr;18(4):421-7. doi: 10.5588/ijtld.13.0688. PMID: 24670696; PMCID: PMC4060979
  6. Huaman MA, Sterling TR, Shepherd BE, Fiske CT. 25-Hydroxyvitamin D levels after recovery from tuberculosis: Insights into pathogenesis. Tuberculosis (Edinb). 2014 Jan;94(1):51-4. PMCID: PMC3938285


  1. Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR. Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int J Tuberc Lung Dis. 2013 Dec;17(12):1531-7. doi: 10.5588/ijtld.13.0423. PMID: 24200264; PMCID: PMC5451112
  2. Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update. Curr Respir Care Rep. 2013 Dec; 2(4):199-207. PMCID: PMC4185413
  3. Pettit AC, Bethel J, Hirsch-Moverman Y, Colson PW, Sterling TR; Tuberculosis Epidemiologic Studies Consortium. Female sex and discontinuation of isoniazid due to adverse effects during the treatment of latent tuberculosis. J Infect. 2013 Nov;67(5):424-32. doi: 10.1016/j.jinf.2013.07.015. Epub 2013 Jul 8. PMID: 23845828; PMCID: PMC3788833
  4. Fenner L, Ballif M, Graber C, Nhandu V, Dusingize JC, Cortes CP, Carriquiry G, Anastos K, Garone D, Jong E, Gnokoro JC, Sued O, Ajayi S, Diero L, Wools-Kaloustian K, Kiertiburanakul S, Castelnuovo B, Lewden C, Durier N, Sterling TR, Egger M; International epidemiological Databases to Evaluate AIDS (IeDEA). Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One. 2013 Oct 17;8(10):e77697. doi: 10.1371/journal.pone.0077697. PMID: 24147059; PMCID: PMC3798412.
  5. Cortes CP, Wehbe FH, McGowan CC, Shepherd BE, Duda SN, Jenkins CA, Gonzalez E, Carriquiry G, Schechter M, Padgett D, Cesar C, Madero JS, Pape JW, Masys DR, Sterling TR; Caribbean, Central American, South American Network for HIV Research of the International Epidemiologic Databases to Evaluate AIDS. Duration of anti-tuberculosis therapy and timing of antiretroviral therapy initiation: association with mortality in HIV-related tuberculosis. PLoS One. 2013 Sep 16;8(9):e74057. doi: 10.1371/journal.pone.0074057. PMID: 24066096; PMCID: PMC3774609
  6. van der Heijden YF, Maruri F, Blackman A, Mitchel E, Bian A, Shintani AK, Eden S, Warkentin JV, Sterling TR. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. Int J Antimicrob Agents. 2013 Sep;42(3):232-7. doi: 10.1016/j.ijantimicag.2013.04.027. Epub 2013 Jun 24. PMID: 23806638; PMCID: PMC3780576
  7. McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS. 2013 Jul 31;27(12):1933-40. doi: 10.1097/qad.0b013e328360dbb4. PMID: 24180002; PMCID: PMC3879806
  8. Bordelon H, Russ PK, Wright DW, Haselton FR. A magnetic bead-based method for concentrating DNA from human urine for downstream detection. PLoS One. 2013 Jul 8;8(7):e68369. doi: 10.1371/journal.pone.0068369. PMID: 23861895; PMCID: PMC3704639
  9. Chang KC, Sterling TR, Yew WW. Are we ready to shorten the treatment duration for non-cavitary pulmonary tuberculosis? Int J Tuberc Lung Dis. 2013 Jun;17(6):712. PMID: 23676152
  10. Shepherd BE, Jenkins CA, Parrish DD, Glass TR, Cescon A, Masabeu A, Chene G, de Wolf F, Crane HM, Jarrin I, Gill J, del Amo J, Abgrall S, Khaykin P, Lehmann C, Ingle SM, May MT, Sterne JA, Sterling TR. Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis. AIDS. 2013 May 15;27(8):1321-9. PMCID: PMC3992322
  11. Pettit AC, Cummins J, Kaltenbach LA, Sterling TR, Warkentin JV. Non-adherence and drug-related interruptions are risk factors for delays in completion of treatment for tuberculosis. Int J Tuberc Lung Dis. 2013 Apr;17(4):486-92. doi: 10.5588/ijtld.12.0133. Epub 2013 Feb 7. PMID: 23394818; PMCID: PMC3981539
  12. Richmond BW, Ploetze K, Isom J, Chambers-Harris I, Braun NA, Taylor T, Abraham S, Mageto Y, Culver DA, Oswald-Richter KA, Drake WP. Sarcoidosis Th17 cells are ESAT-6 antigen specific but demonstrate reduced IFN-γ expression. J Clin Immunol. 2013 Feb;33(2):446-55. doi: 10.1007/s10875-012-9817-6. Epub 2012 Oct 18. PMID: 23073617; PMCID: PMC3850764


  1. Hiatt LA, Cliffel DE. Real-time Recognition of Mycobacterium tuberculosis and Lipoarabinomannan using the Quartz Crystal Microbalance. Sens Actuators B Chem. 2012 Nov 1;174:245-252. doi: 10.1016/j.snb.2012.06.095. Epub 2012 Aug 19. PMID: 23175600; PMCID: PMC3500912
  2. Oswald-Richter KA, Beachboard DC, Seeley EH, Abraham S, Shepherd BE, Jenkins CA, Culver DA, Caprioli RM, Drake WP. Dual analysis for mycobacteria and propionibacteria in sarcoidosis BAL. J Clin Immunol. 2012 Oct;32(5):1129-40. doi: 10.1007/s10875-012-9700-5. Epub 2012 May 3. PMID: 22552860; PMCID: PMC3526106
  3. Blackman A, May S, Devasia RA, Maruri F, Stratton C, Sterling TR. Microcolonies in fluoroquinolone agar proportion susceptibility testing of Mycobacterium tuberculosis: an indicator of drug resistance. Eur J Clin Microbiol Infect Dis. 2012 Sep;31(9):2177-82. doi: 10.1007/s10096-012-1552-7. Epub 2012 Feb 10. PMID: 22322359; PMCID: PMC3981548
  4. van der Heijden YF, Maruri F, Blackman A, Holt E, Warkentin JV, Shepherd BE, Sterling TR. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis. 2012 Sep;16(9):1162-7. doi: 10.5588/ijtld.12.0046. Epub 2012 Jul 12. PMID: 22794509; PMCID: PMC3981533
  5. Kernodle DS. Warning: differences in the copy number of duplication unit 2 (DU2) within BCG Danish 1331 may influence findings involving genetically modified BCG Danish strains. Vaccine. 2012 Sep 14;30(42):6013-4; author reply 6015. doi: 10.1016/j.vaccine.2012.01.023. Epub 2012 Feb 10. PMID: 22326901
  6. Person AK, Sterling TR. Treatment of latent tuberculosis infection in HIV: shorter or longer? Curr HIV/AIDS Rep. 2012 Sep;9(3):259-66. doi: 10.1007/s11904-012-0120-1. PMID: 22581360; PMCID: PMC3410968
  7. Fiske CT, de Almeida AS, Shintani AK, Kalams SA, Sterling TR. Abnormal immune responses in persons with previous extrapulmonary tuberculosis in an in vitro model that simulates in vivo infection with Mycobacterium tuberculosis. Clin Vaccine Immunol. 2012 Aug;19(8):1142-9. doi: 10.1128/CVI.00221-12. Epub 2012 Jun 6. PMID: 22675156; PMCID: PMC3416084
  8. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001270. doi: 10.1371/journal.pmed.1001270. Epub 2012 Jul 24. PMID: 22911011; PMCID: PMC3404110
  9. Fiske CT, Griffin MR, Mitchel E, Sterling TR, Grijalva CG. Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis. Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):666-9. doi: 10.1002/pds.3243. Epub 2012 Apr 24. PMID: 22532509; PMCID: PMC3371104
  10. Devasia R, Blackman A, Eden S, Li H, Maruri F, Shintani A, Alexander C, Kaiga A, Stratton CW, Warkentin J, Tang YW, Sterling TR. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. J Clin Microbiol. 2012 Apr;50(4):1390-6. doi: 10.1128/JCM.05286-11. Epub 2011 Dec 21. PMID: 22189117; PMCID: PMC3318526
  11. Sterling TR, Moro R, Villarino ME. Reply to: "Rifapentine and Isoniazid for Latent Tuberculosis". N Engl J Med. 2012 Apr 12;366(15):1448. PMID: 31166682; PMCID: PMC6634941
  12. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, Cambau E, Aubry A. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012 Apr;67(4):819-31. doi: 10.1093/jac/dkr566. Epub 2012 Jan 25. PMID: 22279180; PMCID: PMC3299416
  13. Kernodle DS. SigH, antioxidants, and the pathogenesis of pulmonary tuberculosis. J Infect Dis. 2012 Apr 15;205(8):1186-8. doi: 10.1093/infdis/jis108. Epub 2012 Mar 7. PMID: 22402036
  14. Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C; ACTG 5267 Study Team. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):455-62. doi: 10.1097/QAI.0b013e3182410503. PMID: 22126739; PMCID: PMC3302922
  15. Antas P, Holland S, Sterling T. Abnormal spontaneous interleukin 8 receptor expression: a brief report of two cases. Rev Soc Bras Med Trop. 2012 Feb;45(1):134-7. doi: 10.1590/s0037-86822012000100029. PMID: 22370847; PMCID: PMC3981535.
  16. de Almeida AS, Fiske CT, Sterling TR, Kalams SA. Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin Vaccine Immunol. 2012 Jan;19(1):45-52. doi: 10.1128/CVI.05263-11. Epub 2011 Oct 28. PMID: 22038848; PMCID: PMC3255960


  1. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR Jr, Chaisson RE; TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011 Dec 8;365(23):2155-66. doi: 10.1056/NEJMoa1104875. PMID: 22150035
  2. Kipp AM, Pungrassami P, Stewart PW, Chongsuvivatwong V, Strauss RP, Van Rie A. Study of tuberculosis and AIDS stigma as barriers to tuberculosis treatment adherence using validated stigma scales. Int J Tuberc Lung Dis. 2011 Nov;15(11):1540-5, i. doi: 10.5588/ijtld.10.0273. PMID: 22008770; PMCID: PMC3753693
  3. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. 2011 Sep 15;204(6):893-901. doi: 10.1093/infdis/jir421. PMID: 21849286; PMCID: PMC3156918
  4. Kipp AM, Pungrassami P, Nilmanat K, Sengupta S, Poole C, Strauss RP, Chongsuvivatwong V, Van Rie A. Socio-demographic and AIDS-related factors associated with tuberculosis stigma in southern Thailand: a quantitative, cross-sectional study of stigma among patients with TB and healthy community members. BMC Public Health. 2011 Aug 30;11:675. doi: 10.1186/1471-2458-11-675. PMID: 21878102; PMCID: PMC3223813
  5. Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, Shepherd BE, Sterling TR. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):305-10. doi: 10.1097/QAI.0b013e3182182e2d. PMID: 21423024; PMCID: PMC3141096
  6. Manier ML, Reyzer ML, Goh A, Dartois V, Via LE, Barry CE 3rd, Caprioli RM. Reagent precoated targets for rapid in-tissue derivatization of the anti-tuberculosis drug isoniazid followed by MALDI imaging mass spectrometry. J Am Soc Mass Spectrom. 2011 Aug;22(8):1409-19. doi: 10.1007/s13361-011-0150-8. Epub 2011 May 13. PMID: 21953196; PMCID: PMC3424619
  7. Pettit AC, Kaltenbach LA, Maruri F, Cummins J, Smith TR, Warkentin JV, Griffin MR, Sterling TR. Chronic lung disease and HIV infection are risk factors for recurrent tuberculosis in a low-incidence setting. Int J Tuberc Lung Dis. 2011 Jul;15(7):906-11. doi: 10.5588/ijtld.10.0448. PMID: 21682963; PMCID: PMC3172045
  8. Murphree R, Warkentin JV, Dunn JR, Schaffner W, Jones TF. Elephant-to-human transmission of tuberculosis, 2009. Emerg Infect Dis. 2011 Mar;17(3):366-71. doi: 10.3201/eid1703.101668. PMID: 21392425; PMCID: PMC3166032
  9. Swaisgood CM, Oswald-Richter K, Moeller SD, Klemenc JM, Ruple LM, Farver CF, Drake JM, Culver DA, Drake WP. Development of a sarcoidosis murine lung granuloma model using Mycobacterium superoxide dismutase A peptide. Am J Respir Cell Mol Biol. 2011 Feb;44(2):166-74. doi: 10.1165/rcmb.2009-0350OC. Epub 2010 Mar 26. PMID: 20348207; PMCID: PMC3049230.
  10. Oki NO, Motsinger-Reif AA, Antas PR, Levy S, Holland SM, Sterling TR. Novel human genetic variants associated with extrapulmonary tuberculosis: a pilot genome wide association study. BMC Res Notes. 2011 Jan 31;4:28. doi: 10.1186/1756-0500-4-28. PMID: 21281516; PMCID: PMC3041678
  11. Bukka A, Price CT, Kernodle DS, Graham JE. Mycobacterium tuberculosis RNA Expression Patterns in Sputum Bacteria Indicate Secreted Esx Factors Contributing to Growth are Highly Expressed in Active Disease. Front Microbiol. 2012 Jan 10;2:266. doi: 10.3389/fmicb.2011.00266. PMID: 22291682; PMCID: PMC3254194


  1. Chambers IR, Cone TR, Oswald-Richter K, Drake WP. Enzyme-linked immunospot assay (ELISPOT): Quantification of Th-1 cellular immune responses against microbial antigens. J Vis Exp. 2010 Nov 23;(45):2221. doi: 10.3791/2221. PMID: 21178951; PMCID: PMC3159592
  2. Oswald-Richter KA, Beachboard DC, Zhan X, Gaskill CF, Abraham S, Jenkins C, Culver DA, Drake W. Multiple mycobacterial antigens are targets of the adaptive immune response in pulmonary sarcoidosis. Respir Res. 2010 Nov 23;11(1):161. doi: 10.1186/1465-9921-11-161. PMID: 21092305; PMCID: PMC2999599
  3. Richmond BW, Drake WP. Vitamin D, innate immunity, and sarcoidosis granulomatous inflammation: insights from mycobacterial research. Curr Opin Pulm Med. 2010 Sep;16(5):461-4. doi: 10.1097/MCP.0b013e32833af7e8. PMID: 20473167
  4. Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int J Infect Dis. 2010 Sep;14 Suppl 3:e60-6. doi: 10.1016/j.ijid.2009.11.012. Epub 2010 Mar 1. PMID: 20189863; PMCID: PMC2905608
  5. Oswald-Richter KA, Drake WP. The etiologic role of infectious antigens in sarcoidosis pathogenesis. Semin Respir Crit Care Med. 2010 Aug;31(4):375-9. doi: 10.1055/s-0030-1262205. Epub 2010 Jul 27. PMID: 20665387
  6. Kernodle DS. Decrease in the effectiveness of Bacille Calmette-Guérin vaccine against pulmonary tuberculosis: a consequence of increased immune suppression by microbial antioxidants, not overattenuation. Clin Infect Dis. 2010 Jul 15;51(2):177-84. doi: 10.1086/653533. PMID: 20524854
  7. Sterling TR, Pham PA, Chaisson RE. HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis. 2010 May 15;50 Suppl 3:S223-30. doi: 10.1086/651495. PMID: 20397952
  8. Motsinger-Reif AA, Antas PR, Oki NO, Levy S, Holland SM, Sterling TR. Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med Genet. 2010 Mar 2;11:37. doi: 10.1186/1471-2350-11-37. PMID: 20196868; PMCID: PMC2837863
  9. Light RW. Update on tuberculous pleural effusion. Respirology. 2010 Apr;15(3):451-8. doi: 10.1111/j.1440-1843.2010.01723.x. Epub 2010 Mar 21. PMID: 20345583
  10. Kernodle DS, Sadagopal S, Kalams SA. Re: Misleading comments in Ranganathan et al. "Recombinant pro-apoptotic Mycobacterium tuberculosis generates CD8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice". Vaccine. 2010 Feb 25;28(9):2064-5. doi: 10.1016/j.vaccine.2009.12.029. Epub 2009 Dec 25. PMID: 20038429
  11. Horsburgh CR Jr, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, Hughes S, Shrestha-Kuwahara R, Sterling TR, Wall K, Weinfurter P; Tuberculosis Epidemiologic Studies Consortium. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010 Feb;137(2):401-9. doi: 10.1378/chest.09-0394. Epub 2009 Sep 30. PMID: 19793865
  12. Oswald-Richter K, Sato H, Hajizadeh R, Shepherd BE, Sidney J, Sette A, Newman LS, Drake WP. Mycobacterial ESAT-6 and katG are recognized by sarcoidosis CD4+ T cells when presented by the American sarcoidosis susceptibility allele, DRB1*1101. J Clin Immunol. 2010 Jan;30(1):157-66. doi: 10.1007/s10875-009-9311-y. Epub 2009 Jun 18. PMID: 19536643; PMCID: PMC2821522
  13. Fiske CT, Griffin MR, Erin H, Warkentin J, Lisa K, Arbogast PG, Sterling TR. Black race, sex, and extrapulmonary tuberculosis risk: an observational study. BMC Infect Dis. 2010 Jan 22;10:16. doi: 10.1186/1471-2334-10-16. PMID: 20096113; PMCID: PMC2823615